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Introduction: Peripartum cardiomyopathy (PPCM) is a heart disease of unknown aetiology emerging in 
previously healthy women towards the end of pregnancy or first postpartum months. Previous studies have 
suggested that oxidative stress contributes to the pathogenesis of PPCM. Melatonin is a powerful endogenous 
antioxidant that can limit the damaging effect of oxidative stress. Melatonin levels are known to be altered in 
sleep disruption, depression and other cardiac diseases. The aim of this study was to determine if melatonin 
levels are disrupted in women with PPCM compared to healthy patients. We hypothesised that sleep 
disruption and depression may contribute to a disruption in their melatonin levels. 
Subjects and Methods: Pregnant and postpartum healthy control (HC), with (PPCM) or women with other 
cardiac diseases (CD) were recruited for the study.  A sleep quality questionnaire and the Edinburgh postnatal 
depression scale (EDPS) were performed in all patients to compare their sleeping patterns and depression 
levels. Daytime and nocturnal salivary melatonin levels were also compared and the serum concentration of 
cortisol and basic natriuretic peptide (BNP) were measured. To evaluate oxidative stress, a thiobartubaric 
reactive substances (TBARS) assay was assessed in the plasma of all women. 
Results: Both BNP levels and oxidative stress were elevated in the postnatal PPCM patients compared to HC 
and CD women. The PPCM and CD groups demonstrated increased EDPS scores and elevated serum cortisol 
compared to HC. The postnatal PPCM women also demonstrated delayed, fragmented, inefficient sleep 
compared to the other women. The PPCM women had significantly higher (p<0.05) postpartum nocturnal 
melatonin (99.8±8.8pg/ml) levels compared to HC (73.4±8.3 pg/ml) and CD (77.8±7.8pg/ml) (p<0.05).  
Interpretation: The postnatal PPCM women demonstrated an increase in oxidative stress, in salivary 
nocturnal melatonin, in EDPS scores and sleep disruption, therefore suggesting that disruption in the 
melatonin synthesis, associated with depression and sleep disturbances, may play an important role in the 
development the disease. Further studies will be required to delineate whether melatonin may be considered as 
a therapeutic target for patients with PPCM. 
 

















CHAPTER 1: INTRODUCTION 
1. PERIPARTUM CARDIOMYOPATHY (PPCM) 
1.1 Definition of PPCM 
 
Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease of unknown 
etiology, emerging in previously healthy women towards the end of pregnancy or during the first 
postpartum months1. Women with PPCM present with initial left ventricular (LV) systolic 
dysfunction and symptoms of heart failure (Figure 1)2. The first reference to PPCM  in the medical 
literature was in 1849, but the condition was only recognised as a distinct entity in 19373. The 
disease affects women with no previous history of cardiac disease and occurs by definition in the 
final month of pregnancy, or during the first 5 months postpartum4. This time interval may, however, 
lead to under diagnosis, an alternative definition has recently been suggested to extend to "an 
idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic 
dysfunction towards the end of pregnancy or in the months following delivery, where no other cause 
of heart failure (HF) is found"5. The diagnosis of PPCM is challenging as, the early detection is 
hampered by an overlap of symptoms of the normal peripartum period. A final diagnosis can only be 
made by the exclusion of all other causes of HF6. The condition is therefore probably under reported, 
although current data suggest that it is a leading cause of pregnancy related morbidity and mortality3.  
 
 














1.2 Epidemiology and prevalence of PPCM 
 
The full epidemiological incidence of PPCM is largely unknown due to the diagnosis being one of 
exclusion6. There is a large geographical and racial discrepancy in the occurrence of PPCM in 
different populations3. The reported incidence of PPCM per 100000 women in Africa, Asia and the 
United States of America (USA) is shown in Figure 26. The current literature reports the incidence 
to be far higher in developing countries, for example 1 in 300 in Haiti and 1 in 1000 in South Africa 
and China, compared to developed countries such as North American and Europe with 1 in 2500-
40005. African decent is suggested as a possible risk factor. The disease affects regions with large 
African populations such as Nigeria, South Africa and Haiti3. Regions in developed countries with 
large numbers of socio-economically disadvantaged population groups, such as Georgia, compared 
to the more wealthy state of California in USA,  also show higher frequencies of PPCM6.  
 
 
Figure 2. The reported incidence of peripartum cardiomyopathy in North America, Asia and Africa. The condition 
remains relatively rare in developed regions such as California and is more common in developing regions such as Haiti, 












1.3  Pathophysiology, symptoms and diagnosis of PPCM 
 
Major compensatory changes are made by the maternal heart to accommodate the demands of  
pregnancy and lactation7. During pregnancy, women experience a reversible cardiac hypertrophy and 
reduced relaxation of diastolic function but, in healthy women, this regresses to normal following 
childbirth (Figure 3)8. In the case of PPCM, the maternal heart does not regress to normal and 
deteriorates9.  It has been suggested that anti-angiogenic signalling, during pregnancy and post 
partum may contribute to the development of PPCM. Anti-angiogenic factors in the placenta secretes  
vascular endothelial growth factor (VEGF) inhibitors such as soluble Vascular endothelial growth 
factor receptor 1 (Flt1)10, high levels of circulating levels of Flt1 are known to lead to cardiac 
dysfunction, particularly in mice lacking pro-angiogenic Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α). Women who develop PPCM have been shown to have high 
levels of sFlt110. 
 The diagnosis of PPCM is often delayed due to the variability of the clinical manifestations, as well 
as similarities to other types of HF secondary to cardiomyopathy (CM)11. Patients with PPCM often 
present with elevated LV end-diastolic pressure due to systolic dysfunction and a diagnosis can only 
be made once all other causes of HF have been excluded5. The early signs and symptoms may be 
mild or mirror those of normal pregnancy5. The presenting symptoms, which include fatigue and 
dyspnoea (shortness of breath) on mild exertion, are often mistaken for other conditions such as 
pneumonia or complications related to delivery, causing a delay in referral to cardiologists11. Other 
symptoms include pedal oedema, orthopnoea, dizziness and palpitations5. A list of common 
presenting signs and symptoms is shown in Table 111. An electrocardiogram (ECG) and 
echocardiography are useful in excluding other forms of heart failure which may help the diagnosis5. 
The ECG often includes changes such as abnormal rhythms, including skipped beats and arrhythmias 
(Table 1)
11. The echocardiogram demonstrates changes including LV dilation, as well as reduced 
ejection fraction (EF)11. The B-type natriuretic peptide (BNP) and N-Terminal BNP (NT-pro BNP) 
are often elevated in women with PPCM5. BNP has an important function in the regulation of 
cardiovascular and renal homeostasis, as well as in the regulation of fatty acid metabolism and body 
weight12. Studies have demonstrated a positive correlation between the extent of cardiac damage and 
BNP concentration12. BNP is therefore a useful tool in the diagnosis and treatment monitoring of 
PPCM12. Serum microparticles have recently been shown to be a potentially useful tool in the 

















Figure 3. Proposed mechanism for the pathogenesis of PPCM. During pregnancy the heart undergoes hypertrophic 
changes. In normal women the heart returns to normal following delivery, however in some women possibly due to 
factors such as an increase in oxidative stress or other factors leads to heart failure. Following the development of PPCM 














































1.4 Risk factors and proposed mechanisms of PPCM 
 
The current data is suggestive that a complex interaction between genetic factors, combined with the 
physiological adaptation of pregnancy and childbirth, contributes to the development of PPCM14. 
The exact causative factors of PPCM are unclear. A number of factors have been suggested to 
contribute to the condition, including pregnancy-related factors such as age, number of children, 
toxolytic ingestion and malnutrition5. The other suggested factors include the general cardiovascular 
risk factors such as smoking, hypertension and diabetes5. A diagram of probable, proposed and 
emerging risk factors for the development of PPCM is shown in Figure 46. PPCM likely results from 
a complex interaction between a combination of multiple factors, including socio-economic and 






Figure 4. The proposed,  probable and emerging risk factors which possibly contribute to the development of peripartum 














1.4.1 Role of genetics in PPCM 
 
The geographical and racial discrepancies, as well as anecdotal evidence noting familial clustering in 
PPCM, is suggestive of a genetic cause. However, this has not been established3. Some reports 
suggest that the cases in which related women have been diagnosed with PPCM are in fact cases of 
dilated cardiomyopathy (DCM) unmasked by the hemodynamic stress of pregnancy15. The 
presentation of PPCM is similar to DCM11.  These studies also suggest that PPCM may be part of the 
DCM spectrum, with related mutations6. A model of DCM in mice who have an over-expression of 
the alpha (α) subunit of the protein Gq in cardiac tissue have been shown to develop pregnancy-
induced cardiomyopathy8. This has, however, not been shown to translate into human women who 
develop PPCM8. A genetic component cannot be fully excluded, although most of the evidence 
points to the risk factors being a combination of other factors rather than hereditary5.  
1.4.2 Role of inflammation in PPCM 
 
Inflammation is a biological response of the immune system on vascular tissues to stimuli such as 
damaged cells, irritants and pathogens16. There is evidence to suggest that inflammation has a role in 
the pathophysiology of PPCM7. The activation of pro inflammatory cytokines and elevation of C-
reactive protein (CRP) is a major characteristic of HF3. CRP is a group of acute phase proteins which 
specifically bind to phosphocholine and recognize target membranes of reactive and apoptotic cells4. 
Forster et al. investigated whether such reactive proteins CRP and tumour necrosis factor alpha 
(TNFα), as well as apoptosis antigen 1 (Fas/Apo-1), could predict the outcome in patients with 
PPCM17. The study found that the plasma markers for inflammation, as well as Fas/Apo-1, were 
increased significantly and in direct proportion to an increase in LV size and a decrease in EF17. A 
study by Sliwa el al., in South Africa, documented the clinical outcomes relative to inflammatory 
markers in 100 PPCM patients4. The CRP and the inflammatory cytokine interleukin-6 (IL6) levels 
were significantly raised in more than half of the women who developed PPCM4. The study also 
suggested that low total cholesterol was a predictor of poor outcome, larger LV dimensions and 
lower EF4.  
 
Sliwa et al. performed a study to further understand the mechanisms underlying PPCM in humans17. 
The baseline serum markers relating to apoptosis, oxidative stress remodelling, inflammation and 
cardiac function were analysed in women with PPCM and healthy controls17. The patients were 
followed up at 6 months and were either categorised as improved or not improved17. The majority of 












group compared to healthy controls. The results also suggested a correlation between oxidative 
stress, inflammation and prolactin17. Baseline NT-pro BNP levels were significantly higher in the 
PPCM group that did not improve after 6 months17.  
  
1.4.3 Role of prolactin in PPCM 
 
Hilfiker-Kleiner et al. highlighted the fact that the transcription factor signal transducer and activator 
of transcription 3 (STAT3) functions in a diverse number of physiological situations, including heart 
function with what appears to be opposite functions, including proliferation and apoptosis18. The 
down regulation of STAT3 is associated with late-stage heart failure and the activation of STAT3 is 
associated with the survival of cardiomyocytes and angiogenesis18. The study by Hilfiker-Kleiner et 
al. included mice with a cardiomyocyte specific deletion of STAT3, which are sensitive to cardiac 
insult18. Oxidative stress is enhanced in these mice which leads to cardiac cathepsin-D mediated 
cleavage of prolactin into a 16kDa pro apoptotic form. As a consequence, these mice suffer high 
mortality, heart failure and a decrease in cardiac angiogenesis which are hallmarks of PPCM18. 
Hilfiker-Kleiner et al. also demonstrated a reduction in the STAT3 protein in the heart tissue of 
women with PPCM in comparison to healthy controls19. The study also demonstrated an increase in 
oxidized low-density lipoprotein (oxLDL) in the patients with PPCM19. The down regulation of 
STAT3 and the fragmentation of the 23kDa breastfeeding hormone, prolactin, into the 16kDa pro 
apoptotic form is shown in Figure 5. A separate study also determined that a failure to reduce 
oxLDL and prolactin in women diagnosed with PPCM was an predictor of poor outcome20. 
 
In light of the prolactin research, Twickler et al. proposed that the matrix metalloproteinase of 
trophoblastic cells could facilitate the cleavage of prolactin and possibly contribute to PPCM and 
pre-eclampsia21. Pre-eclampsia, like PPCM, is a pregnancy specific condition characterised by 
hypertension and protein urea21. There is a high co-morbidity between PPCM and pre-eclampsia and 
further research is needed to determine whether there is indeed a connection21. In Africa, low plasma 
levels of the antioxidant  selenium (Se) level have been reported as a possible risk factor for PPCM22. 
Combs et al. suggested that Se deficiency plays a role in PPCM, but not as a direct causative factor22. 
These studies suggest that oxidative stress is a significant contributor to the development of PPCM 























Figure 5. Role of prolactin in PPCM and  the mechanism of action of bromocriptine. Bromocriptine blocks the 
production of 23kDa prolactin from the pituitary gland. This prevents the cleavage of prolactin into the 16kDa pro 
apoptotic form and this likely leads to an improvement in women with PPCM. Recently the inhibition of microRNA145a 
















1.5 Treatment and prognosis 
 
A certain percentage of women with PPCM do recover and their LV function normalises (Figure 
4)24. The remaining portion often suffers from major adverse effects following PPCM, including 
mortality in up to 25% of women with PPCM24. In women who recover, there a risk for reoccurrence 
remains in future pregnancies and women with previous PPCM diagnosis should be monitored in 
subsequent pregnancies25. Poor outcome was particularly associated with women whose LV function 
had not returned to normal2. Early diagnosis of the condition is essential for the initiation of 
appropriate medical care and counselling for future prognosis19.  
Currently, PPCM is treated with standard heart failure drugs, including angiotensin-converting 
enzyme (ACE) inhibitors, diuretics, aldosterone antagonists, and beta-blockers19. Special attention 
should be given to safety if ACE inhibitors are administered during pregnancy, due to their potential 
teratogenic effects3. Bromocriptine, an inhibitor of prolactin release from the pituitary gland, is a 
promising treatment for PPCM19. The mechanism of action of bromocriptine in the treatment of 
PPCM is shown in Figure 519. A prospective, proof-of-concept pilot study was performed at a single 
centre in South Africa by Sliwa et al., comparing the use of bromocriptine and standard HF drugs in 
the treatment of PPCM,-over a period of 8 weeks26. The results of the study found no significant 
difference in baseline characteristics in serum 16-kDa prolactin levels and cathepsin D activity26. The 
group who received bromocriptine did, however, display a greater LV EF and a lower mortality rate 
than the group on standard heart failure treatment26. When bromocriptine is used, the entire prolactin 
cascade is inhibited which excludes breastfeeding (Figure 6)27. A new promising target for the 
treatment of PPCM, further downstream the prolactin cascade is the microRNA-146a (Figure 6)27. 
MicroRNAs are short, non-coding small sequences which post-transcriptionaly alter gene expression. 
Recently the 16Kda has been shown to induce microRNA-146a expression in endothelial cells, 
which attenuated angiogenesis through down regulation of neuroblastoma rat sarcoma (NRAS) 
(Figure 6)27. The inhibition allows the maintenance of normal nursing due to the downstream 
























Figure 6. Role of miRNA-146a in PPCM and proposed alternative treatment by maintaining normal prolactin functions. 
Figure 6A: Cleavage of prolactin which increases miR-146a expression. Figure 6B: Blocking prolactin completely by 
use of bromocriptine eliminates the 16 kDa pro apoptotic prolactin, but stops breastfeeding. Figure 6C: Use of anti-miR-


















2. OXIDATIVE STRESS 
2.1 Definition of oxidative stress 
 
Oxidative stress involves a shift towards the pro-oxidant side of the pro-oxidant/antioxidant 
balance28. This functions in a wide range of pathological progress and is increasingly being 
recognized as a major contributing factor in a large number of diseases28. Oxidative stress is caused 
by free radicals, unstable atoms or molecules which have an unpaired electron and are reactive due to 
their tendency to bind in order to complete the pair29. Reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are two classes of free radicals in the oxidative stress pathway30. The ROS 
family includes, the superoxide anion (O2-), hydrogen peroxide (H2O2) and the hydroxyl radical 
(OH)28. ROS are beneficial in a variety of cellular physiological processes, including their 
bactericidal properties30. When there is an excess of ROS, the beneficial effects are negated by the 
negative effects of oxidative stress and include protein denaturation, lipid fragmentation as well as 
the destruction of enzymes and deoxyribonucleic acid (DNA)30. RNS is a by-product of normal 
endothelial metabolism28. The nitrogen oxide (NO) radical also has many helpful and harmful 
processes28. The molecule can exist in various forms as fully reduced nitrogen or fully oxidised 
nitrate28. Peroxynitrite is formed when O2- and NO are produced in near equimolar ratio31. 
Peroxynitrite has multiple damaging effects, including DNA damage, as well as lipid peroxidation31. 
Many factors can influence the overproduction of superoxide anion radical in both the cytosol and 
mitochondria32. Following the overproduction of superoxide anions and the oxidation of essential 
molecule nitro oxidative stress, peroxynitrite forms and causes cellular damage 32. First, peroxynitrite 
has direct toxic effects leading to lipid peroxidation, protein oxidation, and DNA damage32. 
Secondly, this leads to the induction of transcription factors which induce an inflammatory cascade 
and chronic inflammation32. 
 
 The shift in the oxidative balance occurs when the production of free radicals exceeds the 
antioxidant capacity (pathways which provide protection against the harmful effects of free 
radicals)33. The reaction which ROS and RNS produce, is a reduction-oxidation (redox) reaction34 35. 
During a redox reaction a pair of electrons from the oxidized molecule are transferred to the reduced 
molecule (ROS or RNS) and energy is released35. 
 
RNS and ROS have short half lives and are therefore difficult to measure directly33. Oxidative stress 
can be measured indirectly, either by a decrease in total antioxidant capacity or  by the estimation of 












2.2 Oxidative stress during pregnancy and postpartum 
 
The oxidative process during pregnancy has a regulatory function36. The regulation of vascular 
changes, as well as the uterine and cervical tone in the maternal body, is dependent on the 
mechanisms involving the metabolic pathways of ROS and RNS37. At the start of pregnancy, an 
inflammatory cascade is activated which allows the formation and invasion of the foreign 
trophoblastic material into the maternal tissues28. These pathways also control normal and pathologic 
embryogenesis28. The production of NO and RNS are essential at this point, by modulating the 
metalloproteinase which functions to remodel the uterine extracellular matrix37. The hormone 
oestrogen mediates the regulation of the balance of the pro-oxidative and anti-oxidative molecules 
guarding this process28. An increase in oxidative stress during pregnancy can be characterised by 
enhanced lipid peroxidation and the circulation of lipid hydroperoxides and MDA28.  
 
The placenta is rich in iron, a transitional metal which is important in the production of free 
radicals38. The increase in oxidative stress in healthy women peaks around the second trimester38. 
When the pregnancy becomes advanced, disruption in this oxidative balance can lead to an 
inappropriate activation of the inflammatory cascade, which produces harmful effects, including 
premature labour and complications such as pre eclampsia28. A study by Mittal et al. compared the 
levels of 3 oxidative stress markers, glutathione peroxidase, superoxide dismutase and MDA, as well 
as the 2 antioxidants (vitamin C and lycopene) in healthy and pre-eclamptic pregnant women39. The 
study observed that women with pre-eclampsia had higher levels of oxidative stress markers and 





















2.3 Oxidative stress and cardiovascular disease 
 
Oxidative stress plays a central role in the pathogenesis of cancer, atherosclerosis, aging and other 
chronic diseases40. ROS and oxidative damage are known contributors to the damage associated with 
ischemia-reperfusion (I/R) injury40. The lack of oxygen to the tissues, as observed in ischemia, is 
damaging. However the restoration of blood is equally destructive as it is associated with an 
excessive production of free radicals41. Atherosclerosis is a chronic vascular disease in which 
inflammation and oxidative stress are implicated as major causative factors of the disease41. This 
leads to excessive deposits of oxLDL in large arteries due to inflammation and oxidative stress41.  
 
Oxidative stress is known to be enhanced in myocardial remodelling and failure42. Established risk 
factors of cardiac disease such as hypertension, high fat diet and smoking are all associated with an 
increase in oxidative stress40. Sustained increases in oxygen radical production in the mitochondria 
may lead to a destructive cycle of mitochondrial DNA damage, as well as functional decline, further 
ROS generation and cellular injury (Figure 7)42. The additional increase in ROS induces myocyte 
hypertrophy, apoptosis, and interstitial fibrosis by activating matrix metalloproteinases42.  
 
As mentioned previously, oxidative stress is a major emerging contributor to the development of 
PPCM19. In women with PPCM, an increase in oxidative stress, as well as a reduction in 
cardioprotective STAT3, leads to  prolactin cleavage and contributes to the LV dilation associated 


































Figure 7. Schematic representation of a link between reactive oxygen species (ROS), mitochondrial DNA damage and 
respiratory chain dysfunction in the mitochondria. Mitochondrial ROS generation may lead to a catastrophic cycle of 
mitochondrial functional decline, further ROS generation, and cellular injury. ETC, electron transport chain in a failing 






















2.4 Endogenous and exogenous antioxidants 
 
An endogenous antioxidant defence system protects cells from oxidative damage and may act via 
enzymatic or non-enzymatic pathways28. The non-enzymatic antioxidants, including  Vitamin A, E 
and C, as well as selenium, help to protect tissue against damage by preventing the initial formation 
and blocking the propagation of ROS28. The most effective oxidant scavengers include superoxide 
dismutase (SOD), catalase and glutathione peroxidase (GSH-Px). Antioxidants have been shown in 
experimental studies to protect against the harmful effects of oxidative stress, however this has not 
been translated to randomised clinical trials40. Antioxidants may still prove a potential therapeutic 
tool in the prevention and treatment of cardiovascular disease40.     
 
 
Exogenous antioxidants may be consumed in the form of supplements or dietary intake. Individuals 
who consume a typical western diet, high in trans fats and grains and low in fruits and vegetables are 
at risk for trace element and vitamin deficiency29. A diet rich in fruits and vegetables has been shown 
to reduce the risk of cardiovascular disease35. The mechanism by which this protection is conferred 
has been difficult to prove and the antioxidant effect has been suggested35. Studies in Europe have 
demonstrated a low plasma concentration of  micronutrients (iron, selenium, zinc, vitamins B1, B6, 
C, A and E) in healthy individuals29. Vitamin E has been extensively studied in large prevention 
trails, but no benefit has been demonstrated40.  A randomised placebo-controlled supplemented 
women at risk for pre-eclampsia with high doses of vitamins E and C (VIP trial)43. The 
supplementation did not decrease the risk of pre-eclampsia in these women and the risks of high 
doses of these antioxidants during pregnancy were concluded to be unjustified43. The conclusion that 
the antioxidants do not contribute to the protection may be premature, as the physiological dose may 
be incorrect or the wrong type of antioxidants are being used35. An antioxidant which has shown 




















3.1 Definition and structure of melatonin 
 
Melatonin is a methoxyindole hormone synthesized and secreted by the pineal gland  from 
tryptophan, taken up from the circulation and converted to melatonin by a 2 step enzyme transfer45. 
Melatonin is well known as a "sleep hormone" and acts as a time giver, essential to both the timing 
and onset of circadian rhythm and reproduction46. Melatonin is also a powerful natural antioxidant, 
able to easily reach cellular and sub cellular compartments, due to its small size and amphiphilic 
nature47. Melatonin acts as an endogenous free radical scavenger and broad spectrum antioxidant47. 
In the presence of oxidants, melatonin generates the powerful antioxidant products, cyclic 3-
hydroxymelatonin (c3OHM) and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK)48. The free 
radical scavengers c3OHM and AFMK both lead to the formation of N1-acetyl-5-
methoxykynuramine (AMK), which in turn is also a free radical scavenger (Figure 8)48. Nutritional, 
environmental, and chemical factors can induce the overproduction of the superoxide anion radical in 
both the cytosol and mitochondria49. Melatonin is  secreted by the hypothalamic circadian pacemaker 
which is synthesised from serotonin in the pineal gland under limiting influence of norepinephrine50. 
Mitochondria, the powerhouse of the cell, have a high intracellular level of melatonin47. 
Mitochondria are particularly important in the formation of ROS which, when produced in excess, 
damage the mitochondrial lipids proteins and DNA47. Cardiolipin, a phospholipid on the inner 
membrane of the mitochondria, is known to be involved in several mitochondrial bio-energetic 
processes such as apoptosis47. Changes to cardiolipin structure has been associated with 
mitochondrial dysfunction and oxidative stress47. Melatonin has been reported to protect the 














Figure 8. The antioxidant cascade of melatonin. When melatonin interacts with oxidants cyclic 3-hydroxymelatonin 
(c3OHM) and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) is generated. Both c3OHM and AFMK are 
powerful antioxidants themselves, leading to the formation of N1-acetyl-5-methoxykynuramine (AMK). From Russel et 
























3.2 Melatonin rhythm in humans 
 
Human average melatonin levels are lowest during daytime hours and peak around 2-4am (Figure 9) 
50. Figure 9A shows the plasma melatonin levels in humans and Figure 9B shows the salivary 
melatonin levels which correlate to the plasma, although at a lower concentration50. Melatonin 
secretion is lowered by pulses of bright light at night, and by a variety of drugs such as beta 
blockers49. Melatonin secretion has also been shown to be lowered in humans who consume caffeine 
on a regular basis49. Melatonin is generally not released during the day and increases 2hours before 
sleep onset and declines during the morning hours. Melatonin should be measured under controlled 
light conditions as even dim light can suppress melatonin release50.  
 
There are individual differences in the timing and onset of the release of melatonin51. Humans can be 
classified as either "morning people", these individuals tend to be more fatigued at night and rise 
earlier51, whereas "evening people" tend to be more active at night and rise later in the morning, with 
more fatigue51. Data suggest this is due to individual differences in the timing and onset of melatonin 
release51. The use of exogenous melatonin supplementation has previously been reported to induce 
drowsiness and sleep and has been suggested to be beneficial in alleviating sleep disturbances and 
nocturnal akawkenings52. The influence of eye  colour on the suppression of melatonin secretion of 
bright light was studied by Higuchi et al.53. The study compared individuals with light eye colour 
(green or blue) compared to dark eye colour (brown)53. The study found that salivary melatonin was 
significantly more suppressed in individuals with light eye colour compared to dark53. These data 



































Figure 9. Figure 9A: the plasma melatonin levels in 10 healthy humans between the hours of 21h00 and 9h00. Figure 






















3.3 Melatonin levels during pregnancy and postpartum  
 
The changes in serum melatonin concentrations and their roles in pregnancy are not clear46. Pregnant 
women also wake more frequently as the foetus grows. They also often suffer nocturia and difficulty 
sleeping comfortably as the pregnancy advances54. Nutritional, environmental and other factors such 
as pregnancy can induce the overproduction of superoxide radicals in the cytosol and mitochondria47. 
Oestrogen and progesterone are known modulators of the amplitude and phase of the circadian 
rhythm54. It is possible that changes in these hormones during pregnancy may alter the rhythm in 
these women, predisposing them to mood alterations as well as sleep disruption54. Nakamura et al. 
investigated changes in serum melatonin concentrations in normal and several pathologic 
pregnancies in humans with a special focus on pre-eclampsia46. Serum melatonin levels have been 
shown to be suppressed in the first trimester, corresponding with the increase in oxidative stress 
(Figure 10A)46. Serum melatonin levels thereafter rise, peaking in the final trimester, and return to 
baseline postpartum (Figure 10A)46. An increase in oxidative stress has been suggested to contribute 
to the pathogenesis of pre eclampsia46.  In women with severe pre-eclampsia the serum melatonin 
levels were significantly lower than in healthy controls (Figure 10B) 46. These data suggest that the 
decrease in melatonin may contribute to the increase in oxidative stress46.  
 
Evidence in the literature suggests that melatonin levels return to baseline shortly after birth46. 
Melatonin, as well as circadian sleep rhy hm, have conversely been shown to be disturbed in the 
postpartum period47. Postpartum women often wake up more frequently to care for their infant47. 
Stempiank et al. performed a study on the effect of melatonin on the secretion of the nursing 
hormones oxytocin and prolactin in rats55. The study found that concentrations of 1ng/ml of 
melatonin significantly inhibited the secretion of prolactin in nursing female rats55. A similar study 
performed on ewes, demonstrated that, controlled exogenous melatonin supplementation decreases 
prolactin secretion56. Melatonin may also have additional beneficial effects46. Light is a well known 
trigger for the eclamptic seizure and melatonin is a well known anticonvulsant46. Melatonin provided 




































Figure 10. Figure 10A:The changes in serum melatonin at night time (solid line) and daytime (dotted line) during a 
normal singleton pregnancy from conception to postpartum.. Figure 10B: the serum melatonin levels in normal 
pregnancy (white) or pregnancy with mild preeclampsia (hatched) or severe preeclampsia (black). *P<0.01, **P<0.05. 























3.3 Melatonin and the pathophysiology of cardiovascular disease 
 
Oxidative stress is a strong causative factor in aging and cardiovascular disease32. Therapy with 
antioxidants is a promising treatment in such diseases32. Previous studies have, however, failed to 
show a benefit in using supplementation with classical antioxidant vitamins A, E and C32. Melatonin 
is a  multifunctional indolamine which counteracts virtually all pathophysiological conditions and 
displays significant beneficial actions against peroxynitrite-induced cellular toxicity32. Melatonin is 
also a powerful  scavenger of both RNS and ROS, including those formed from peroxynitrite, and 
blocks transcriptional factors, which induce pro inflammatory cytokines32. A preliminary study 
suggests that melatonin levels are lower in coronary artery disease45. Evidence in the literature 
indicates that melatonin is a promising therapy, either alone or in combination with other 
antioxidants, in conditions with oxidative stress32. Several studies have investigated the effect of 
melatonin supplementation in atherosclerosis41. Preliminary experimental studies in animal models 
have suggested that melatonin protects the heart and  other organs from I/R injury by scavenging the 
free radicals41.  
 
Studies have demonstrated that melatonin has a promising effect on reducing blood pressure (BP)57. 
The hypotensive effect of melatonin is unclear, but may be explained by the free radical scavenging 
effects or the endothelial relaxing effects of melatonin57. Preliminary human trials have demonstrated 
that, a daily dose of 1mg of melatonin reduced BP in young men and women, compared to placebo 
supplementation57. Figure 11 demonstrates the physiological regulation of melatonin and its 
protective effects on the cardiovascular system58. In response to light and dark stimuli, melatonin 
secretion from the pineal gland regulates the melatonin release. This, in turn, has multiple 





























Figure 11. Physiological regulation of melatonin by the light/dark environment as detected by the retina. The light dark 
response and melatonin secretion from the pineal gland regulate the melatonin release. This in turn has multiple 
pleiotrophic effects on the heart including anti-inflammatory, antioxidant and antihypertensive properties. From 





















3.3.1 Melatonin and inflammation in cardiovascular disease 
 
A study by Lecour's group demonstrated that melatonin activates the powerful cardioprotective 
survivor activating factor enhancement (SAFE) pathway in male mice59 60. Previous animal models 
have demonstrated that an excess production of inflammatory cytokines, such as TNFα and IL6, 
contribute to heart failure. However, clinical trials targeting a suppression of inflammatory cytokines 
in heart failure have failed to translate to humans59. Melatonin has been demonstrated to activate the 
SAFE pathway by activating TNF and TNF receptors on the cell membrane (Figure 12)59. Once 
TNF is bound to its receptor, the Janus kinase/signal transducers and activators of transcription 3 
(JAK/STAT3) pathway is activated59. When activated, JAK proteins are phosphorylated and form a 
docking site for the activation of STAT3 proteins59. The phosphorlyation of STAT3 allows homo-
dimerisation and the STAT3 proteins are transported to the mitochondria and induce the transcription 
of pro-survival genes59.  
 
Figure 12. Melatonin activates the survivor activating factor enhancement (SAFE) pathway. Melatonin has been shown 
to activate TNF which binds on its cell surface receptor and subsequently activates the janus kinase/signal transducer and 
activator of transcription 3 (JAK/STAT3) signalling pathway. After phosphorylation, signal transducer and activator of 













4. SLEEP QUALITY AND CIRCADIAN RHYTHM 
4.1 Sleep and circadian rhythm 
 
A circadian rhythm is defined as any biological rhythm which displays an endogenous cycle of 24 
hours61. This rhythm is entrained by external zeitgebers (time givers), in particular, the response to 
light and dark by the hormone melatonin62. The oscillation of the circadian rhythm in humans is 
controlled by a small group of clock genes within the cell nuclei62. These genes are then regulated by 
a master biological clock in the suprachiasmatic nuclei (SCN)62. The SCN gives the precise time 
cues which regulate a diverse range of physiological, hormonal and behavioural daily patterns62. A 
summary of some of the circadian rhythms in humans is shown in Figure 1345. Sleep has been 
characterised by a state of absent or reduced consciousness and the inactivity of all voluntary 
muscles63.  
 
Sleep can be roughly categorised into two main forms, rapid eye movement sleep (REM) and non 
rapid eye movement sleep (non REM) 63. The non REM sleep is further divided into 4 stages63. 
Gross brain wave activity during sleep may be measured by the use of an electroencephalogram 
(EEG). The REM and non REM stages of sleep and the relevant EEG pattern is shown in Figure 14. 
While awake, most people show alpha and beta EEG wave patterns. These beta waves have high 
frequency, low amplitude, and are desynchronous64. During relaxation, the waves begin to slow 
down and become more synchronous and the EEG amplitude decreases demonstrating more alpha 
type waves65. The first stage of non REM sleep is characterized by theta waves, which are even 
slower in frequency and greater in amplitude than the alpha waves65. As the sleeper moves to stage 2 
sleep theta wave activity continues. Stages 1 and 2 are relatively "light" stages of sleep65. When 
individuals are awakened in stages 1 or 2, they often do not realise they have been asleep65. Humans 
pass from the theta waves of stage 1 and 2, to the delta waves of stage 3 and 4. Delta waves are the 
slowest and the highest amplitude brain waves65. Delta sleep is considered as the deepest sleep, the 
waves being vastly different from the waking brain waves. If an individual wakes up in stages 3 or 4, 
they are usually sleepy and disoriented65. Following the first 4 stages, humans then enter the REM 
sleep, characterised by rapid eye movement and a dramatic loss of muscle tone. During REM sleep 
the waves are similar to the waking state and this stage is associated with dreaming65. The brain 
waves then usually either return to an awake state or cycle back to stage 265. A full cycle from stage 
1 to REM takes approximately 90 minutes65. Throughout the sleep cycle, the delta stages decrease 
until waking65. Any disruption such as frequent waking during the sleep cycle or an insufficient sleep 














Figure 13. Circadian rhythms are 24 hour cycles including:  melatonin, sleep/wakefulness, cortisol and 



















4.2 Sleep quality 
 
Globally, with increasing economic and social demands, the population is rapidly evolving into a 
24hour permanently awake society66. Increasingly, humans are working outside of the normal 0800–
1700 h working day, with up to 20% of the population working  outside of these hours66. The 
negative effects of the change in working hours on sleep loss and, subsequently health, are currently 
being appreciated66. The normal circadian rhythm in individuals with changes in sleeping patterns is 
disrupted64. In humans, sleep is normally initiated by the nocturnal response to dark, accompanied by 
an increase in melatonin and a decline in temperature66. Any change in the normal sleep-wake cycle 
leads to physiological disturbances, such as melatonin secretion, which has a domino effect on blood 
pressure, increases in the stress hormone, cortisol, as well as activation of the inflammatory and 
oxidative stress pathways66. Attempts to sleep in an inappropriate phase of the circadian cycle 
usually result in shorter sleep duration and more nocturnal awakenings66. Primary insomnia 
(difficulty sleeping) is a sleep disorder not caused by organic or psychiatric condition67. Insomnia 
involves a difficulty of initiating, as well as maintaining, sleep67. Daytime naps have been shown to 
increase alertness and sleep efficiency following a disturbed night sleep68. Measuring the sleep 
quantity is an important measure of sleep efficiency69. This is however not always directly correlated 
with the quality of sleep69. Nocturnal awakenings are more predicative of sleep quality69. Introduced 
in 1989, the Pittsburgh sleep quality index (PSQI) is a useful tool to measure sleep quality in 























4.3 Sleep quality during pregnancy and postpartum  
 
Pregnant women report that during pregnancy their sleep is disrupted70. Sleep deprivation has been 
linked to increases in pro inflammatory cytokine levels70. Okun and Coussons-Read. investigated the 
effect of the altered sleeping patterns on the serum inflammatory cytokines of pregnant women, 
compared to non pregnant women70. The study found that CRP levels, TNF alpha, as well as IL10, 
significantly correlated with sleep loss during pregnancy70. Elevated pro inflammatory cytokines 
during pregnancy have been linked with conditions such as postpartum depression, pre-eclampsia 
and PPCM70. Sleeping time has been shown to increase during pregnancy, peaking at 33-36 weeks 
and decreasing again towards delivery.71 
Although sleep is known to be disrupted in the postpartum period, very few studies have investigated 
this phenomenon. Thomas et al. investigated the level and timing of melatonin in postpartum and 
non pregnant women over a 24 hour period47. The study found a significantly different pattern of 
melatonin between the two groups47. Postpartum women were found to have a higher baseline and 
lower maximum melatonin levels, thus suggesting a disruption in circadian rhythm during the 
postpartum period47. Mancini et al. performed a study on  the sleep disturbances on non depressed 
postpartum women72. The study found that the total sleep time was not as badly affected as the 
























4.4 Sleep and cardiovascular health 
 
 
Epidemiological studies suggest that circadian disruption contributes to an increased risk in obesity, 
cardiovascular disease and diabetes73. Experimental investigations of sleep deprivation and 
fragmentation have been found to alter immune responses, as well as increase the circulation of 
inflammatory markers74. Circadian disruption has been shown to increase serum concentration of 
CRP, an established marker of inflammation and cardiovascular disease75. There have been multiple 
self-reported cases and anecdotal evidence that poor sleep quality and continuity are common in HF 
patients76. A study conducted with post operative cardiac patients indicate that sleep disruption 
contributes to declines in functional performance, as well as in mental health77. The physical and 
mental effects of sleep disruption have been suggested to be a risk factor, as well as a predictor of 






























5.1 Definition of depression 
 
Depression is a state of low mood which forms part of a set of mood disorders78. Mood disorders 
include major depression, seasonal affective disorder, bipolar illness and postpartum depression78. 
Major depression or unipolar depression is a clinical state of low mood, with loss of interest or 
pleasure and interferes with daily functioning79. Seasonal affective disorder, has a similar 
presentation to major depression, except with symptoms being more severe or only present in winter 
months80. Bipolar depression involves sometimes rapidly changing mood states from a depressive to 
a manic state80. It has been suggested that up to 20% of all adults will suffer a mood disorder 
requiring treatment in their life time78. There is no currently biological test for clinical depression, a 
diagnosis is made using psychiatric interview by a qualified psychiatrist78. The diagnosis in both 
clinical practice and research studies by signs and symptoms is presented in Table 2. Sleep 
disturbances, fatigue, lack of concentration and motivation are examples of symptoms of major 
depression in the diagnostic and statistical manual of mental disorders IV (DSM IV)78.  
  













5.2 Depression during pregnancy and postnatal depression 
 
Peripartum depression is a serious and prevalent mental health condition81. Depression is disabling 
for women and is most common during the childbearing years81. Postpartum depression refers to the 
depressions occurring during the postpartum period up until the first year following childbirth81. In 
developed countries studies have shown that the prevalence of postpartum depression is around 10-
15%82. In developing regions, this percentage is often doubled. A study in Western Nigeria reported 
the incidence of maternity blues to be 31.3%83. A South African study identified that 32% of the 
perinatal women screened for maternal depression qualified for referral to counselling84. This case 
study claimed that there is a deficiency in screening in the primary health care in South Africa and 
that many cases are not identified84. The study used the Edinburgh Postnatal Depression Scale 
(EDPS) as a screening tool84. The EDPS is a validated 10 item questionnaire used for screening for a 
probable diagnosis of depression both pre and postpartum85 82. In a separate study performed in peri-
urban settlements in Cape Town, South Africa investigated the prevalence of depressed mood during 
pregnancy in this population85. The study found that 39% of the pregnant women showed signs of 
depression. Depression is also a common psychiatric complication resulting from Human 
immunodeficiency virus (HIV), which is prevalent in South Africa86. The symptoms of postpartum 
depression are similar to those of major depression and they often overlap with anxiety symptoms81. 
The psychosocial risk factors for maternal and postpartum depression include past history of mental 
illness, mental disturbance during pregnancy, family history of depression, low socioeconomic status 
and poor interpersonal relationships87. Postnatal depression is sometimes preluded by depression 
during maternity88. Bunevicius and colleagues investigated psychosocial risk factors for depression 
during pregnancy88. They determined that low education,  psychosocial stressors and  previous 



















5.3 Depression and cortisol 
 
Cortisol is a glucocorticoid steroid hormone produced by the zona fasciculata of the adrenal cortex89. 
The hormone is released in response to stress and is commonly elevated in psychiatric conditions 
such as anxiety and depression89. Cortisol levels, like melatonin, follow a circadian rhythm. The 
normal levels of cortisol therefore vary throughout the day (Figure 15) 90. Previous studies have 
reported that blood cortisol levels are higher in pregnant woman91. In the third trimester, it has been 
reported that salivary cortisol is twice the values of non pregnant women91. Other reports suggest that 
cortisol can increase up to three-fold during pregnancy92. This increase generally returns to baseline 
shortly after birth93. Significantly higher cortisol levels have been reported in postpartum women 
with psychiatric illness93. Goodwin et al.  reported an average early morning serum cortisol level in 
pregnant women of 30.55 ±9.95 ng/ml94. Bhai et al. used the EDPS to measure depression and 
plasma to measure hormones in pregnant, postpartum and non gravid women. The study found that 
postpartum women had significantly increased cortisol, prolactin and oestrogen than non gravid 
women93. Depressed postpartum women also had lower levels of prolactin93. Women who has 
breastfed had lower EDPS scores93. 
 














5.4 Depression as a risk factor for cardiovascular disease 
 
Since the times of the ancient Greeks, affective dispositions have been thought to be associated with  
physical disease95. Depression is known to be a risk factor for the development of cardiovascular 
disease, as well as a predictor of poor prognosis following a cardiac event96. Established risk factors 
such as hypercholesterolemia, hypertension and smoking do not fully correlate to the ischemic heart 
disease incidence97. Psychosocial factors have been suggested to account for these differences97. The 
mental and physiological changes of a depressive individual may also negatively affect the course of 
the disease96. The decrease in the patient's motivation may result in noncompliance with medical 
recommendations, as well as other factors such as smoking and hypertension96. Previous animal and 
human models have shown links in the pathways between depression and anxiety with physiological 
responses95. Physiologic changes such as nervous system activation, an increase in inflammation, 
sleep pattern changes and cardiac rhythm disturbances96. A recent longitudinal  study found a 25 year 
decrease in life expectancy in individuals with severe mental illness, not from suicide, but from 
cardiovascular disease98. 
 
Inflammatory markers such as CRP, TNF-α and IL6 have been associated with an increased risk for 
cardiovascular disease99. Vaccarino and colleagues investigated the depression, inflammation and 
cardiovascular outcomes of women99. This study found an increased risk of cardiovascular disease 
was associated with established depression99. The study found that women with established 
depression had 70% higher CRP levels than women without depression99. The study found that 
although established depression was associated with a higher cardiovascular risk, possible depression 
was not99. The study also suggested that the association between depression and cardiovascular 
disease cannot be explained by inflammation alone99. Stewart and colleagues performed a 
prospective study to determine the directionality of the association between depression and 
inflammatory markers in both men and women100. The study found that only body mass index had a 
greater association with increased CRP and IL6 than depression100. 
Developing countries have higher frequencies of PPCM, pre-eclampsia and perinatal depression 
compared to the developed world101 82. The mechanism by which depression is thought to contribute 
is through an increase in oxidative stress and inflammation99. Oxidative stress and inflammation have 
both been suggested to contribute to the development of PPCM and pre-eclampsia4 102. Depression 
and anxiety during pregnancy may contribute to hypertension via excretion of vasoactive hormones 












and anxiety in early pregnancy was a risk factor for pre-eclampsia later in pregnancy103. The 
oxidative stress and inflammation increased by depression may lead to the development of left 



































5.5 Melatonin and depression 
 
Circadian rhythm disturbance is a major feature of mood disturbances54. A study by Taki et al. 
investigated the relationship between poor sleep quality, mental stress and salivary melatonin 
concentrations104. The study found that subjects with poor sleep quality had, on average, higher 
nocturnal melatonin values104. The study also found individuals with higher anxiety and depression 
also demonstrated a higher nocturnal melatonin value104. This has been suggested to be due to the 
natural defence response to increase in oxidative stress caused by change in diet or lifestyle in 
response to mental stress104. Chronic poor sleep quality is likely to increase the melatonin 
concentration in defence against the sleep disruption104. Parry et al. measured the levels of plasma 
melatonin in depressed pregnant and postpartum women105 54. The study noted that plasma melatonin 
levels were lower in pregnant and higher in postpartum depressed wome  compared to healthy 
controls (Figure 16)54. These findings suggest that melatonin levels in depressed women are likely 




Figure 16. Mean plasma melatonin concentrations at successive time points in Healthy Controls (HC; closed circles) 














PPCM is a heart disease of unknown aetiology emerging previously healthy women towards the end 
of pregnancy or in the first postpartum months. The exact pathophysiology of PPCM remains 
unclear, however the extensive work of Hilfiker-Kleiner et al. suggests that oxidative stress mediates 
the cleavage of the nursing hormone prolactin into a 16kDa pro apoptotic form which contributes to 
PPCM. Melatonin is a powerful endogenous antioxidant that can limit the damaging effect of 
oxidative stress. Melatonin levels are known to be altered in sleep disruption as well as depression. 
In the present study we hypothesise that, an alteration in the levels of the powerful antioxidant 
hormone melatonin, may contribute to the pathophysiology of PPCM. 
Figure 17 presents the hypothesis that sleep disruption and depression during pregnancy/postpartum 
may affect the production of the antioxidant melatonin and increase the oxidative stress, leading to 
prolactin cleavage and the development of PPCM. 
 
Figure 17. This study investigates whether a disruption in the antioxidant melatonin, possibly due to an increase in 
depression and/or sleep disruption leads to an increase in oxidative stress thereby causing the cleavage of prolactin into 












To explore this hypothesis, patients with or without PPCM were recruited from the cardiac disease in 
maternity clinic (CDMC), Groote Schuur Hospital (GSH), Cape Town South Africa as well as the 
general maternity clinic and the following experiments were performed (Figure 18): 
1. Questionnaires were administered to the patients to determine the self reported depression and 
sleeping pattern disruptions. 
2. Blood samples were taken from the patients to measure markers of oxidative stress and antioxidant 
capacity. Cortisol levels were assayed to determine the levels of the stress hormone in the patients. A 
BNP fragment assay was used as a measure of the severity of heart failure. 




Figure 18. Summary of patient recruitment and sample collection. Late pregnant or early postpartum women with 
PPCM, other cardiac disease (CD) or healthy women (HC) were recruited for the study. The women were given 













CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Patient recruitment and sample collection 
 
Pregnant (third trimester) and postpartum women of childbearing age (18-45) were recruited for the 
study (Figure 19). Women with PPCM on stable therapy were the experimental group. The majority 
of patients were diagnosed in the first months postpartum, even though the initial signs and 
symptoms had been present towards the end of pregnancy11. The pregnant PPCM group are women, 
previously diagnosed with PPCM, who are at risk for reoccurrence. Women with other pre-existing 
cardiovascular disease in maternity (CD), such as cardiomyopathy (CM) or congenital heart disease 
(CHD), were also recruited. The PPCM and CD groups were recruited from the CDMC at Groote 
Schuur hospital (GSH), Cape Town, South Africa. Healthy control (HC) women, without any known 
cardiovascular disease, were recruited from the maternity ward at GSH. A total of 24 HC (12 
postpartum and 12 pregnant), 40 CD (23 pregnant and 17 postpartum) and 14 PPCM women (5 
pregnant and 9 postpartum) were recruited (Table 3). This project is an extension of the research 
activities in the CMDC at Groote Schuur Hospital (HREC/ref:176:2010). The study has been 
approved by the UCT Human Ethics Research Committee (HREC/ref:246:2012). 
Table 3. Number of pregnant and postpartum HC, CD and PPCM patients recruited for the study 
   
 HC CD PPCM 
Pregnant 12 23 5 
Postpartum 12 17 9 




















The women were questioned using two separate questionnaires to measure their depression risk, as 
well as the quality of their sleeping patterns. Two tubes of blood (one coated with 
ethylenediaminetetraacetic acid (EDTA) to collect plasma and one without for serum collection) was 
collected from each patient, between 10 and 11am, and taken back to the lab for processing. The 
tubes were spun down for 5 minutes at 2200 rpm at 4°C. The samples were then stored at -80°C until 
analysis. 
 
 For the collection of saliva, each patient was given 2 saliva collection tubes (Salivette®, Sardstedt, 
Germany) and a set of pictorial (Appendix A) and written instructions according to manufacturers 
guidelines (Figure 19). The patients were instructed to avoid bright light in favour of muted light. 
The patients were also instructed not to consume any food 30 minutes prior to the collection of the 
samples and to avoid eating bananas and chocolate for the entire day before. They were also 
instructed not to consume caffeinated beverages or alcohol on the evening of collection. The patients 
were instructed to provide baseline samples at 12pm and nocturnal samples at 2am. The tubes were 
then collected from the patients, processed and stored at -80°C until analysis. 
 
 
Figure 19. Patient saliva collection instructions provided for each patient. The patients were each supplied with 2 tubes 
for  samples at time points 12pm (baseline) and 2am. The patients were instructed to refrigerate the samples and return 













2.2 Basic natriuretic peptide (BNP) fragment enzyme immunoassay 
 
The measurement of B-type natriuretic peptide (BNP) concentrations in blood is a useful marker of 
heart failure12. The BNP hormone is part of a family of structurally similar hormones, including 
atrial natriuretic peptide (ANP), C-type natriuretic peptide (CNP), and urodilatin12. The BNP and 
ANP are secreted by ventricular myocytes, although BNP is mainly secreted from the left ventricle 
and is the most commonly used as a marker of heart failure12. BNP preferentially binds to a 
membrane-bound guanylyl cyclase (GC) receptor. The peptide plays an important role in the 
regulation of cardiovascular and renal homeostasis, as well as the regulation of fatty acid metabolism 
and body weight. The major precursor protein of BNP is proBNP, which is cleaved to form BNP and 
biologically inactive NT-proBNP (Figure 20)12 106 . There remains a debate when and where the pre 
hormone is split. Data from in vitro experiments suggests the proteolytic enzyme, fusin is responsible 
for the cleavage107. This cleavage, releases active BNP which leads to natriuresis, diuresis, 
vasodilatation and smooth muscle relaxation12. ANP performs similar functions to BNP, but is 
produced by the atria12. The serum concentrations of serum BNP rise in pathological states, such as 
in ventricular dilation or reduced clearance of peptides (renal failure)12. Studies have shown the 
greater cardiac damage, the greater the BNP concentration12.  
 
 














The BNP fragment levels in the serum of all patients, were quantified using a BNP fragment assay as 
per manufacturer's instructions (Biomedica, Netherlands, BI-20852W). BNP fragments in the serum 
are very heterogeneous. Mature BNP consists of 108 amino acids (proBNP and BNP), and undergoes 
cleavage resulting in the function of the physiologically active BNP-32, as well as physiologically 
inactive N-terminal peptide comprising amino acids 1-76, which is further degraded proteolytically. 
 
The serum samples and kit reagents were defrosted on ice, then acclimatised to room temperature 
(RT). 150μl assay buffer was aliquoted into each well of a microtiter plate, followed by 30μl of the 
standards. Positive controls and human samples were added into the wells in duplicate. The BNP 
fragments in the serum samples bind to the antibodies pre-coated on the plate (Figure 20). 50μl of 
the conjugate was then added and the plate was swirled gently, to coat the unbound antibodies. The 
plate was then sealed and incubated overnight in the dark. The following day, the liquid was 
aspirated and the wells were washed 5 times with 300μl of the wash buffer. The substrate (200μl) 
was added into each well to bind to the conjugate. The plate was then incubated for 20 minutes at RT 
in the dark. The stop solution (50μl) was added and the plate and the absorbance was measured at 
450nm, with a reference at 630nm (Spectramax plus384 fluorescence spectrophotometer (Abotech, 
South Africa) using Softmax pro software (version 4.4)). The absorbance measured is inversely 
proportional to the BNP concentration. A standard curve was plotted and the BNP concentration 
expressed in pmol/L of the samples was calculated by extrapolating the values from the standard 
curve (Figure 22). The serum BNP concentration was converted to pg/mL using the manufacturer 
recommended conversion factor of 8.475. According to the European Society of Cardiology (ECS) 















Figure 21. The principle of the BNP fragment assay. The wells of the commercial microtiter plate are coated with BNP 
specific antibodies. Either BNP from the standards or samples binds to the antibodies. The conjugate binds to the 
remaining antibodies. The substrate binds to the conjugate and the relative fluorescence is measured at an optical density 
(OD) of 450nm. The intensity of the fluorescence of the conjugate/substrate reaction is inversely proportional to BNP 
concentration of the samples.  
 
 
BNP assay standard curve












Figure 22. Basic naturietic peptide (BNP) fragment assay standard curve generated from samples with known 
concentrations of BNP. The intensity at optical density of 450nm  is inversely proportional to the BNP concentration of 















2.3 Thiobarbituric acid reactive substances assay (TBARS) 
 
Oxidative stress has been suggested to potentially contribute to the pathogenesis of PPCM18. The 
direct measurement of ROS is challenging because of their very short half lives109. It is therefore 
preferable to measure the damaged by-products, rather than the ROS themselves109. The 
thiobarbituric acid reactive substances (TBARS) are formed subsequent to lipid peroxidation  and 
may be detected using thiobarbituric acid (TBA) as a reagent109. The assay measures 
malondialdehyde (MDA), a low molecular weight end product of lipid peroxidation109.  
 
To measure the MDA in the plasma of all patients, a TBARS assay was performed according to the 
method of Jentzsch et al. 110. A schematic diagram of the method used is shown in Figure 23. 
Initially, 50µl of plasma was aliquoted in duplicate into 1.5ml Eppendorf® tubes and  mixed with 
6.25 µl of butylated hydroxytoluene (BHT/C2H5OH)(Fluka-Chemie, Buchs, Switzerland) in ethanol 
(Merck Chemicals, Cape Town, South Africa) as well as 50µl 0.2M phosphoric acid (Merck 
Chemicals, Cape Town, South Africa). The tubes were then vortexed. 6.25µl of 0.1M TBA reagent 
in 0.1M NaOH) (Sigma-Aldrich, Cape Town, South Africa) was added and the tubes were vortexed 
again. The tubes were incubated at 90°C for 45 minutes on a heating block and the reaction was 
stopped by cooling the tubes in ice for 2 minutes. MDA was extracted with 500µl n-butanol and 50µl 
saturated NaCl to facilitate phase separation. The mixture was centrifuged at 2000rpm for 2 minutes. 
300 µl of the top butanol phase of  samples were aliquoted into a flat bottomed 96 well microtiter 
plate. The absorbance was read at an OD of 532nm 572nm (reference range) on a Spectramax 
plus384 fluorescence spectrophotometer (Abotech, South Africa), using Softmax pro software 
(version 4.4), and values were expressed in µmol of MDA per litre of plasma. The Beer-Lamberts 
law was used to calculate the concentration of MDA in the samples with an extinction coefficient of 





































2.4 Oxygen radical absorbance capacity (ORAC) 
 
The shift in the oxidative balance occurs when the production of free radicals exceeds the antioxidant 
capacity (pathways which provide protection against the harmful effects of free radicals)33. The total 
antioxidant capacity of the plasma (of all patients) was assessed using the oxygen radical absorbance 
capacity (ORAC) assay. This assay evaluates the samples intrinsic antioxidant protective effect of a 
plasma sample against oxidative degradation of a fluorescent molecule fluorescein (3, 6, 
dihydroxyspiro(isoberyofuran-1(3H),9(9H)-xanthen)(disodium)(Sigma-Aldrich,Germany), following 
mixing with 2,2′-azobis (2-amidinopropane)dihydrochloride (AAPH), a peroxyl radical generator111. 
The fluorescent intensity of the fluorescein decreases as the oxidative damage of the free radicals 
released by AAPH progresses. The protection against the free radicals generated by AAPH of the 
plasma is compared to known concentrations of the vitamin E analogue trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylicacid (Sigma-Aldrich, Germany).. 
A 0.075M pH 7.4 phosphate buffer was prepared and used in all dilutions (Appendix B). Different 
concentrations of trolox were also prepared (Appendix B). Working stock of fluorocein was 
prepared from stock solutions (Appendix B). To extract the protein from the plasma, 200µl ice cold 
ethanol was added to 100µl of plasma. The mixture was then centrifuged at 12000 rpm at 4°C for 5 
minutes. The protein free supernatant was then diluted 363x in the phosphate buffer. The trolox 
standards of known concentrations and plasma samples were aliquoted onto a white flat-bottomed 
microtiter plate with the phosphate buffer and fluorcein. Warm 0.032M of AAPH was then added to 
each well and the samples were read over a period of 2 hours at an excitation wavelength of 425nm 
and an emission wavelength of 520nm on a Varian Cary eclipse fluorescence spectrophotometer (Set 
point tech., South Africa). The decay curve of intensity of fluorescence vs time was recorded of the 
samples and trolox standards recorded. The area under the decay curve over 2 hours of each known 
concentration of trolox was calculated (Figure 24). A standard curve was generated using the known 
concentrations of trolox, compared to the area under the curve (Figure 25). The area under the curve 
is inversely proportional to the antioxidant capacity as a small area indicates faster decay and less 
protection against the free radicals generated by AAPH. The area under the decay curve over time of 
the patient plasma samples was calculated and the concentration of trolox equivalents of antioxidant 















Figure 24. Decrease in fluorescence over time in difference of different concentrations of the vitamin E analogue trolox. 
The area under each curve was for each  concentration trolox in nmol was used to generate a standard curve. 
 
 

















2.5 Questionnaire selection and design 
 
A questionnaire is an important tool to gather information in the medical field112. The design of a 
questionnaire, such as attention to flow, format and length is of importance to ensure that the 
questionnaire establishes the correct information.112. The first recommended step in the decision to 
use a questionnaire is to perform a literature search and investigate what type of questionnaires have 
been previously used112. Previously used questionnaires have already been validated and are 
preferable. Only when no appropriate questionnaire is available should a new questionnaire be 
designed as this is a tedious process112. When designing a questionnaire, the appropriateness of the 
content, level of language sophistication, sequence and how data is sought from the respondents (self 
administered or investigator administered) need to be taken into consideration. 
 
The validity of a questionnaire is the degree to which the assessment measures what it is designed to 
measure. There are three types of validity i) content validity, ii) criterion- related validity, and iii) 
construct validity. A questionnaire must undergo a validation procedure to ensure that it will 
accurately achieve its goal. A valid questionnaire must have the following characteristics (i) 
simplicity and viability (ii) reliability and precision in the words (iii) adequacy for the problem 
intended to measure (iv) reflect underlying theory or concept to be measured and (v) capacity to 
measure change112. The types of questions are also important. Open ended questions allow the 
participant to answer in a broad range. Closed ended questions require the participant to answer from 
a predefined set112. To quantify possibly depression, the validated EDPS scale was used directly, as it 
has previously been validated for use in the South African population112. To measure the differences 




















2.5.1 The Edinburgh postnatal depression scale 
 
To screen for possible depression the EDPS was administered to all patients (Figure 26). The EDPS 
scale has previously been validated in South Africa84. The scale is an efficient and reliable screening 
tool for perinatal depression. The questionnaire consists of 10 items and is scored on a scale of 0-3. 
The participants were instructed to answer the questionnaire relating to how they were feeling the 
previous week. Each item consists of a statement and four possible answers. The minimum score is 0 
and the maximum score is 30. A score above 10 warranted further investigation and was considered 









































2.5.2 Sleep quality questionnaire 
 
Introduced in 1989, the Pittsburgh Sleep Quality Index (PSQI) has been accepted as a useful tool in 
different patient groups to assess sleep quality in different somatic conditions67. The PSQI was not 
designed to assess the quality of sleep before, during and after pregnancy. We therefore had to adapt 
the questionnaire, so that it would be more applicable for pregnant and postnatal patients . The sleep 
quality questionnaire that we adapted, was designed to assess the self-reported sleep quality 6 
months prior to pregnancy (baseline), the final month of pregnancy and the first month postpartum. 
The pregnant and postpartum patients, were all were asked the same questions during the interview, 
to recall their current and previous sleeping patterns. 
 
Questions 1-3: Time of onset of sleep and waking 
 
The first question asked the participant what time they went to bed at night. A Likert scale of 5 
options were given (Figure 27). The optimum time for circadian rhythm is between 8pm and 10pm. 
Going to bed before 6pm or after 12pm is considered as an abnormal sleeping rhythm. 
 
The second question asked how long the patient takes to fall asleep at night. Taking long to fall 
asleep (more than 30 minutes to an hour) indicates the participant has some difficulties falling asleep.  
 
The third question asked what time the participant woke up in the morning. Waking up abnormally 
early, (before 12pm or between 1 and 3 am) or abnormally late (after 8am) indicates a disruption in 
circadian rhythm. 
Questions 4-6: Sleep disruption 
 
The fourth question asked how many times the participant woke up at night. A score of 0 was given 
if they never woke up, and a score of 5 was given if they woke more than 5 times. The fifth question 
asked if the patient did wake up, how long they were awake for. This determined whether they had 
the opportunity to complete the sleep cycle. Waking multiple times during the night for long duration 
indicates the participant has a more disturbed sleeping pattern. Question 6 assessed how many hours 
of sleep the participant got at a time between waking. Getting short amounts of sleep between 
















Questions 7-8: Daytime napping 
Evidence in the literature suggests that individuals who take day time naps after a disturbed night’s 
sleep have beneficial effects on their quality of life. Question 7 asked the participant if they took 
daytime naps and question 8 asked how long does the naps lasted for? This determined whether the 
participant benefitted from additional sleep during the daytime hours. A score of 1 was given if the 
participant took daytime naps and their nap time was scored from 1 for (less than 10 minutes) with a 
maximum score of 5 if their daytime naps were longer than 5 hours. A score of 2 was given for 
question 7 if they did not report taking daytime naps. 
Questions 9-10: Sleep efficiency and ease to awake 
Question 9 assessed whether the participant felt fatigued, rested or very well rested following 
sleeping. This was to determine whether their sleep was efficient if they felt rested, or if their sleep 
was disturbed or low quality with them still feeling fatigued on waking. A Likert scale of options 
was given ranging from fatigued (a score of 1), to very well rested ( a score of 5). Question 10 
assessed how easy it was for the participant to wake following sleeping to assess whether they were 
light or heavy sleepers. A score of 1 was given if they were easily awakened, to 5 if they found it 
very difficult to wake. 
Question 11: Caffeine intake 
Question 11 asked the participant how much caffeine they took in units (cups) per day of coke or 
coffee. Caffeine has been shown to decrease melatonin levels and this question investigated whether 
the participants drank excessive caffeine or more than 3 units per day. A score of  0 was given if the 
participants reported that they never consumed caffeine, a score of 1 was given if the consumed 1 















Figure 27. Sleep quality questionnaire comparing sleep quality 6 months before pregnancy, in the final month of 
























2.6 Cortisol quantification by Enzyme-linked immunosorbent assay (ELISA) 
 
Cortisol levels in the serum of the HC, CD and PPCM groups were measured using an ELISA assay 
for human serum or saliva (Immuno-Biological Laboratories, USA) (lot no ECO127). The assay 
measures active free cortisol in saliva or (hydrocortisone and hydroxycorticosterone). Cortisol is a 
hormone which is vital for several functions in the human body89. These functions include the 
regulation of blood pressure, cardiovascular function and the metabolism of carbohydrates, proteins 
and fats. The secretion of cortisol is increased in response to stressors such as trauma, illness or 
psychological stressors89.  
 
 The IBL - America Salivary Cortisol HS ELISA Kit is a solid phase ELISA, based on the principle 
of competitive binding. The serum samples were diluted (1:50) and 50µl of the diluted samples, 
controls and calibrators were loaded onto a 96 microtiter plate in duplicate. The plate is coated with a 
polyclonal rabbit antibody directed towards an antigenic site on the cortisol molecule. A 100 µl of 
enzyme conjugate was aliquoted into each well and the plate was incubated at RT on an orbital 
shaker at (400-600rpm) for 1 minute and then for 120 minutes at RT (18-25°C). The endogenous 
cortisol of the patient samples competes with a cortisol-horseradish peroxidase conjugate for binding 
to the coated antibody. Following incubation the unbound conjugate was washed using wash buffer. 
Substrate solution (100 µl) was then added into each well and the plate was incubated at RT on the 
orbital shaker (400-600rpm) for 30 minutes. The amount of bound peroxidase conjugate is inversely 
proportional to the concentration of cortisol in the sample. After addition of the substrate solution, 
the intensity of colour developed is inversely proportional to the concentration of cortisol in the 
patient sample. A 100 µl of stop solution was then added to each well and the colour changed from 
blue to yellow. The plate was read on a photometer at 450nm and 650nm (reference range) 
(Spectramax plus384 fluorescence spectrophotometer (Abotech, South Africa) within 15 minutes of 
the addition of the stop solution. A standard curve was generated using the standards provided in the 
kit and the cortisol concentration was calculated using the curve as reference (Figure 28). The 












































2.7 Melatonin quantification by Enzyme-linked immunosorbent assay (ELISA) 
 
Melatonin is a powerful natural antioxidant and acts as endogenous free radical scavenger and broad 
spectrum antioxidant47. Melatonin a major regulator of the circadian rhythm of sleep timing and 
onset, is modified during physiological states such as pregnancy and may be altered in 
cardiovascular disease such as high blood pressure46.  
 
The Bülmann direct saliva melatonin ELISA (batch:21.EK.DSM) kit was used to quantitatively 
determine the melatonin content in the saliva of the patients. Saliva collection has advantages over 
plasma and urinary measurements. First, it is more acceptable for participants as it is not painful or 
invasive. Secondly, melatonin secretion peaks at night and patients can be trained to collect the 
samples themselves. Melatonin concentrations in saliva are directly correlated to those in plasma but 
are 70% less concentrated50. The patients were given a set of instructions and 2 saliva collection 
tubes (Salivette®) to collect at 12pm (baseline) and 2am.  
 
The tubes collected from the patients were centrifuged at 3000rpm for 5 minutes. The absorptive 
sponge insert was discarded and 200µl was aliquoted into Eppendorf tubes. The samples and 
standards were then prepared using 25µl of pre-treatment solution, vortexed and incubated at RT for 
10 minutes. The reaction was neutralised using 25µl of neutralising solution and the tubes were then 
vortexed and centrifuged for 5 minutes at 10,000rpm. 
 
The melatonin assay is a competitive immunoassay using a capture (Ab) technique . The polyclonal 
Kennaway G280 anti-melatonin has been pre-coated by the manufacturer onto the microtiter pate. 
The plate was washed twice with 300µl of wash buffer. Immediately, 100µl of blanking reagent, pre-
treated samples, zero calibrator, calibrators, low and high controls were aliquoted into each well in 
duplicate. The plate was incubated at 4°C for 16-24 hours. The following day, 50 µl of biotin 
conjugate was added to each well and the plate was incubated at room temperature on an orbital 
shaker for 1minute (400-600rpm). The plate was then incubated at 4°C for 3 hours. The melatonin in 
the samples and controls competed with biotinylated melatonin. The plate was then washed 4 times 
using wash buffer, followed by 100 µl of enzyme label (streptavidin conjugated to horse radish 
peroxidase) added to all the wells. The enzyme was then allowed to bind to the melatonin-biotin 
complex at room temperature on an orbital shaker for 60 minutes (400-600rpm). The plate was then 
washed 4 times to remove any unbound enzyme, using wash buffer. The tetramethylbenzidine 












them incubated at room temperature on an orbital shaker for 30minutes (400-600rpm). A 
chromophore in reverse proportion to the melatonin present was formed. The stop solution (100 µl) 
was then added and the absorbance was read at 450nm. 
 
To determine the melatonin concentration, the percentage of melatonin bound was calculated by 
dividing absorbance values of the known standard calibrators and multiplying the value by 100 
(Figure 29). The percentage bound was plotted against the known concentrations of the calibrators. 
The sample percentage bound was also calculated by dividing the absorbance values by the zero 
calibrator and the melatonin concentrations were extrapolated using the standard curve. 
 
 
Figure 29. Standard curve generated from known concentrations of melatonin vs percentage bound melatonin at different 
concentrations. The percentage bound was calculated by dividing the average absorbance values by the zero calibrator 





















2.8 Statistical analysis 
 
Statistical analysis of the results were performed using Graphpad Prism 5.0. The results are 
represented as mean ± standard error of the mean (SEM). Standard curves were generated using 
either linear or non linear regression curves. Correlation analysis was performed using Pearson R 
correlation coefficients. Man-Whitney t-tests (two tailed) were performed to compare means in two 
different groups. The test was used because it does not assume that the data are normally distributed. 







































CHAPTER 3: RESULTS 
3.1 Characteristics of study participants 
 
A summary of the characteristics of the study population is shown in Table 3. A total of 78 pregnant 
and postpartum women were recruited for this study (24 HC, 40 CD and 14 PPCM). Of these, there 
were 12 pregnant and 12 postpartum HC, 23 pregnant and 17 postpartum CD and 5 pregnant and 9 
postpartum PPCM women. The pregnant PPCM group were women who were diagnosed with 
PPCM in a previous pregnancy and were pregnant again.  
 
There was no statistically significant difference in the age, BP or body mass index within the groups. 
The mean±SEM age in years for the HC group was 30.0±1.6, the CD group 28±1.4 and the PPCM 
group 29±2.1. The mean BP in millimetres of mercury (mmHg) in the HC group was 122/74, in the 
CD group 120/78 and in the PPCM group 125/80. The mean±SEM BMI in kilograms (kg) per height 
in centimetre (cm) squared of the HC group was 30.1±3.1, the CD group 27±1.3 and the PPCM 
group 27.8±1.2. The mean±SEM heart rate in beats per minute of the HC group was 78, the CD 
group was 84 and the PPCM group was 92. The PPCM group did have a significantly higher heart 
rate compared to the HC (p= 0.01). There was no difference between the HC and CD or CD and HC 
heart rate. The New York Heart Association (NYHA) functional classification (FC) system, most 
recently updated in 1994, is a method of classifying the effect of cardiac disease in patients in 
clinical practice113. The four classes and their relative objective assessments are shown in Table 4. 
The number of women in each functional class are shown in  in Table 3. The number of women who 
were taking ACE inhibitors, beta blockers or bromocriptine is mentioned in the table. Of the 9 
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3.2 Serum concentrations of basic natriuretic peptide (BNP) fragments 
 
The BNP fragment levels in the serum of pregnant or postpartum HC, CD and PPCM women were 
quantified using a BNP fragment assay. BNP levels are a useful marker of heart failure12. According 
to the ESC Guidelines (2012), the optimal upper cut-off/exclusion point for  a healthy physiological 
BNP  is 100pg/mL108. The results of the BNP fragment assay are shown in Figure 30. Figure 30A 
shows the total BNP concentration, expressed in pg/mL, in 14 pregnant and postnatal women with 
PPCM (303±38.1 pg/mL), which is significantly higher than the 34 CD (71.8±24.4 pg/mL, 
p=0.0019) and 20 HC groups (52±5.43,p=0.0011 pg/mL). The HC group was not significantly 
different to the CD group (p=0.2463). There was no difference between the pregnant 10 HC 
(58.21±5.15 pg/mL), 20 CD (68.95±25.45 pg/mL) and 5 PPCM women (70.5±15.36 pg/mL) (Figure 
30B). Figure 30C shows the total BNP concentration in pg/mL in postnatal women, with 9 PPCM 
women (406.05±40.54) presenting a significantly higher level of BNP than the CD group (76.61±5.3, 
p=0.0021) and HC (70±15.7,p=0.0021). The postpartum HC group was not significantly different to 







































Figure 30. BNP fragments concentration in serum by BNP fragment ELISA. The BNP concentration in pg/mL was 
quantified in pregnant and postpartum healthy control (HC), with other cardiac disease (CD) and peripartum 
cardiomyopathy (PPCM) . Figure 30A shows the total BNP fragment concentration in the pregnant and postpartum 
women. Figure 30B shows the BNP fragments concentration in pregnant women. Figure 30C shows the BNP fragments 
concentration in postpartum women. According to ESC guidelines a BNP measurement greater than 100pg/mL is 


















3.3  Measurement of oxidative stress levels. 
 
To measure the oxidative stress levels in the plasma of the pregnant or postnatal HC, CD and PPCM 
women, a TBARS assay measuring plasma MDA concentrations was used/carried out. The results 
are shown in Figure 31. Figure 31A shows that the total MDA concentration expressed in µmol/mL 
in the 12 pregnant and postnatal women with PPCM (1.64±0.45 µmol/mL) is significantly higher 
than that of the 20 HC women  (0.75±0.3 µmol/mL, p=0.0008), but were not higher than that of  the 
34 CD women (1.11±0.44 µmol/mL, p=0.157). The MDA levels in HC women were not 
significantly different from the levels of the CD women (p=0.0821). There was no difference 
between the MDA levels of the 10 pregnant HC (0.67±0.17 µmol/mL), 23 CD (1.44±0.51 µmol/mL) 
and 4 PPCM (1.16±0.24 µmol/mL) women (Figure 31B). Figure 31C shows that the MDA 
concentration in the postnatal PPCM women (1.78±0.52 µmol/mL) was higher than both the levels 




































Figure 31. Thiobarbituric acid reactive substances assay (TBARS) assay for the measurement of 
malondialdehyde (MDA) in µmol/L plasma of healthy control (HC), with other cardiac disease (CD) and peripartum 
cardiomyopathy(PPCM). Figure 31A: The MDA concentration in both pregnant and postpartum women. Figure 31B: 
The MDA concentration in the pregnant women only. Figure 31C: The MDA concentration in the postpartum women 





















3.4 The analysis of plasma antioxidant capacity  
 
The total antioxidant capacity of the plasma from the HC, CD and PPCM pregnant and postpartum 
women was assessed by using the ORAC assay (Figure 32). The 20 pregnant and postpartum PPCM 
women had a total antioxidant capacity of 332.3±47.3 µmol/L trolox equivalents (TE). There was no 
difference between the pregnant and postnatal PPCM women compared to the CD women 
(359.9±65.5 µmol/L, p=0.6187) or the HC women (321.9±64.5 µmol/L, p=0.6926) (Figure 32A). 
There was also no difference between the CD and HC women (p= 0.3286). The ORAC assay did not 
differ between the pregnant PPCM women (365.4±44.3 µmol/L) and the pregnant CD (343.2±54.1 
µmol/L, p= 0.666) or the pregnant HC women (312.9±55.2 µmol/L, p=0.6) (Figure 32B). There was 
also no difference between the CD and HC women (p= 0.2105). A similar trend was observed in the 
postnatal PPCM women (347.7±52.3 µmol/L, compared to the postnatal CD women (376.7±79 



































Figure 32. Oxygen radical absorbance capacity(ORAC) assay to determine the plasma antioxidant capacity in Trolox 
equivalents(µmol/L) in pregnant and postpartum healthy control (HC), with other cardiac disease (CD) and peripartum 
cardiomyopathy PPCM) women. Figure 32A shows both pregnant and postpartum antioxidant capacity. Figure 32B 
shows the antioxidant capacity in pregnant women. Figure 32C shows the antioxidant capacity in postpartum women. 


















3.5 Edinburgh postnatal depression scale (EDPS) 
To screen for possible depression, the EPDS was administered to the pregnant and postpartum HC, 
CD and PPCM women. Figure 33A displays the EDPS score of both the pregnant and postnatal 
women. The mean EDPS score of the HC women was 8.79±2.5, the mean score of the CD women 
was 12.56±3.3 and the mean score of the PPCM women was 14.69±3.3. There was a significant 
difference (p=0.0078) between the HC and PPCM group, as well as between the HC and CD group 
(p=0.0356). There was no significant difference between the CD and PPCM group (p=0.351).  
The pregnant HC women had a mean score of 8.08±2.3, the pregnant CD women had a mean score 
of 13.07±3.2 and the pregnant PPCM women had a mean score of 13.5±3.5 (Figure 33B). The 
pregnant CD group had a significantly higher score than the HC group (p=0.0443). There was no 
significant difference between the pregnant PPCM and the CD group (p=0.1959) or the HC group 
(p=0.8862).  
The postpartum HC women had a mean score of 8.7±2.5, the CD women had a mean score of 
12.23±3.4 and the PPCM women had a mean score of 15.22±3.3 (Figure 33C). The postpartum 
PPCM women had a significantly higher score than the postpartum HC women (p=0.0297). The CD 












































Figure 33. Edinburgh postnatal depression scores (EDPS) in HC, CD and PPCM women. Figure 33A. EDPS of all HC, 
CD and PPCM women. Figure 33B EDPS scores of pregnant HC,CD and PPCM women. Figure 33C EDPS scores of 
postpartum HC, CD and PPCM women. The recommended cut-off for possible depression is a score of 10 or 


















3.6 Sleep quality questionnaire results 
 
Question 1-3: Time of onset of sleep and waking 
 
The results of the mean onset of sleep are shown in Figure 34A. There was no significant difference 
between the sleep onset time of the HC, CD or PPCM women before, during or after pregnancy. 
 
The results of the mean morning waking time are shown in Figure 34B. There was no significant 
difference between the sleep onset time of the HC, CD or PPCM women at any time point. 
 
The results of the mean sleep onset time are shown in Figure 34C. There was no significant 
difference in the baseline sleep onset time between the groups. The PPCM women had a significantly 
longer sleep onset time compared to the HC during pregnancy and postpartum (P<0.05). They also 
had a significantly long sleep onset time compared to the CD group postpartum. There was, however, 






















Figure 34. Figure 34A: The mean score(1-5) of sleep onset time, 1(early)-5(late) before during and after pregnancy in 
the HC, CD and PPCM women. Figure 34B: The mean score(1-5) of morning, 1(early)-5(late) before during and after 
pregnancy in the HC, CD and PPCM women. Figure 34C: The mean score(1-5) of nocturnal sleep onset delay, 1(fast)-
5(delayed) before during and after pregnancy in the HC, CD and PPCM women. (ns: not significant, P<0.05 :*,P<0.01 































Question 4-6: Sleep disruption 
 
Figure 35A shows the number of times the women woke up at night (sleep fragmentation). The 
reported sleep fragmentation of the postpartum PPCM women was significantly higher (P<0.05), 
compared to the HC group. There was a significant increase of sleep fragmentation postpartum and 
during pregnancy within each group, compared to the 6 months before pregnancy (baseline). 
 
The time spent awake between awakening (sleep fragmentation time) is represented in Figure 35B. 
The pregnant (P<0.05) and postpartum (P<0.01) PPCM women had a significantly longer time of 
wakefulness between waking up during the night, compared to HC women. There was also a 
significant increase of waking time during pregnancy in the CD, compared to the HC women 
(P<0.05). 
 
 The total sleep time between the fragmentation is represented in Figure 35C. The postpartum 
PPCM women had a significantly lower sleeping time between fragmentation compared to the CD 
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Figure 35.Figure 35A: The mean number of nocturnal waking before during and after pregnancy in the HC, CD and 
PPCM women. Figure 35B: The mean score (1-5) of morning, 1(short)-5(long) time of being awake during night 
between fragmentation before during and after pregnancy in the HC, CD and PPCM women. Figure 35C: The mean 
score(1-5) of 1(short)-5(long) of the sleep time between fragmentation before during and after pregnancy in the HC, CD 


















Question 7-8: Daytime napping 
 
Figure 36A represents the percentage of HC, CD and PPCM women who undertake naps during the 
day. The percentage of women who took daytime naps increased significantly in each group in the 
final month of pregnancy and postpartum. However, there was no significant difference amongst the 
groups with regards to the percentage of women who took daytime naps. The total amount of 
daytime sleeping or napping is represented in Figure 36B. There was also no difference in total nap 
time between the groups of those women who took daytime naps. 
  
Figure 36 Figure 36A: The percentage of women who took daytime naps before during and after pregnancy in the HC, 
CD and PPCM women. Figure 36B: The mean score(1-5)  1(short)-5(long) of total time of daytime naps before during 























Question 9-10: Sleep efficiency and ease to awake 
 
Figure 37A represents the reported energy following waking. There was a significant general 
decrease in sleep efficiency across all groups (HC, CD and PPCM) during pregnancy and postpartum 
compared to baseline. The postpartum PPCM women reported a significant decrease in sleep 
efficiency compared to CD (P<0.01) and HC women (P<0.001). The CD pregnant women also 
reported a significant decrease in sleep efficiency during pregnancy compared to HC women 
(P<0.01). 
Figure 37B represents the ease to awake. There was no difference observed between the groups. 
 
 
Figure 37. Figure 36A Reported energy following waking before pregnancy(baseline), during pregnancy and postpartum 
in the HC, CD and PPCM women(1: very fatigued, 2: fatigued, 3: rested, 4: well rested, 5:very well rested. Figure 36B 
Reported difficulty waking before pregnancy(baseline), during pregnancy and postpartum in the HC, CD and PPCM 




















There was no difference in the reported caffeine consumption during pregnancy or postpartum 
between the HC, CD and PPCM women (Figure 38). There was a minor (but not significant) 




Figure 38. Reported mean units of caffeine (coke/coffee) per day before pregnancy(baseline), during pregnancy and 




























The serum cortisol levels in the HC, CD and PPCM women were quantified using an ELISA assay. 
The mean cortisol levels of the pregnant and postpartum women are shown in Figure 39A. The 
mean cortisol levels of the pregnant women are shown in Figure 39B and the mean cortisol levels of 
postpartum women are shown in Figure 39C. The mean cortisol concentration in the HC pregnant 
women was 38.5±4.62 µg/dL. The mean cortisol concentration in the HC postpartum women was 
23.7±2.5 µg/dL. Previous studies have reported a 2-3 fold increase in serum cortisol in the final 
trimester, which returned to normal 3 days following childbirth (16-25 µg/dL )91. The pregnant CD 
women had a mean cortisol level of 39.3±4.53 µg/dL. The pregnant CD women did not have 
significantly different cortisol concentrations compared to the HC pregnant women (p=0.708). The 
pregnant PPCM women had mean cortisol concentration of 52.46±5.4 µg/dL. The pregnant PPCM 
women did not have significantly elevated cortisol compared to HC women (p=0.054) but were 
significantly higher than the CD women (p=0.025). 
The postpartum CD women had a mean cortisol concentration of 30.58±5.47 µg/dL, which was not 
significantly different from the HC women (p=0.095). The postpartum PPCM women had a mean 
cortisol concentration of 36.72±5.54 µg/dL. The postpartum PPCM cortisol was not significantly 
elevated compared to the CD women (p=0.219), but was significantly elevated compared to the 




























Figure 39. Cortisol quantification in diluted human serum by ELISA. The cortisol concentration in µg/dL was quantified 
in pregnant and postpartum healthy control(HC), with other cardiac disease(CD) and peripartum cardiomyopathy(PPCM) 
women. Figure 39B shows the cortisol concentration in the pregnant women. Figure 39C shows the concentration in 



















A correlation analysis was performed to compare HC, CD and PPCM EDPS scores with their 
individual serum cortisol concentrations. Figure 40A shows the correlation analysis of the serum 
cortisol (y- axis) vs EDPS score (x-axis) in the HC, CD and PPCM pregnant group. No correlation 
was found between the depression score and the cortisol level in the pregnant women.  Figure 40B 
shows the correlation analysis of the serum cortisol (y-axis) vs EDPS score (x-axis) in the HC,CD 
and PPCM postpartum women. There was a mild positive correlation (r2=0.3394) between the scores 






Figure 40. Figure 40A Correlation analysis between the pregnant group serum cortisol(y-axis) and EDPS score(x-axis). 





















The nocturnal (2am) and daytime (baseline) salivary melatonin concentration was determined in the 
pregnant and postnatal HC, CD and PPCM women by ELISA. There was a significant difference in 
the melatonin levels during the daytime compared to nocturnal (p<0.0001) in each group of women 
(Figure 41A). The combined pregnant and postnatal PPCM women had significantly higher 
nocturnal melatonin (95.7±3.4 pg/mL) compared to the CD (78.3±4.9  pg/mL) (p=0.01) and HC 
women (72.8±5.4  pg/mL) (p=0.0161) (Figure 41A). The daytime melatonin levels of the pregnant 
and postpartum PPCM women (19.2±2.9 pg/mL) were also slightly, but not significantly, elevated 
compared to the pregnant and postpartum CD (13.8±2.9 pg/mL) or HC women (18.5±2.9 pg/mL) 
(Figure 41A). There was no observable difference between the pregnant HC (72.9±7.9 pg/mL), CD 
(78.7±2.9 pg/mL) and PPCM (87.5±4.6 pg/mL) women’s nocturnal melatonin concentrations 
(Figure 41B). There was also no observable difference in daytime melatonin level between all the 
groups. The postpartum PPCM women (99±3.6 pg/mL) had significantly higher nocturnal melatonin 
compared to the CD (77.8±5.2 pg/mL) (p=0.0426)  and HC (73.6±4.5 pg/mL) (p=0.0381) women. 






































Figure 41. Figure 41A. Daytime and nocturnal salivary melatonin concentrations in HC,CD and PPCM pregnant and 
postpartum. . Figure 41B. Daytime and nocturnal salivary melatonin concentrations in HC,CD and PPCM pregnant. . 
Figure 41C. Daytime and nocturnal salivary melatonin concentrations in HC,CD and PPCM postpartum. ( ns: not 

















CHAPTER 4: DISCUSSION 
 
4.1 Summary of results 
 
The aim of this study was to determine a possible disruption in the antioxidant melatonin levels in 
women with PPCM. The study also investigated whether disturbed sleeping patterns and depression 
may possibly contribute to the development of PPCM. A brief summary of the results are shown in 
Figure 42. The results demonstrate an increase in the marker of heart failure, BNP, in postnatal 
PPCM women compared to both CD and HC women. The PPCM women also demonstrated higher 
postpartum nocturnal melatonin levels compared to the HC and CD groups. The oxidative stress, in 
the form of lipid peroxidation, was also elevated in the postnatal PPCM compared to HC and CD 
women. Conversely, there was no observable difference in the antioxidant capacity, in the form of 
trolox equivalents, between the groups. The PPCM and CD groups both demonstrated increased 
EDPS scores and elevated serum cortisol in comparison to the HC women. The PPCM group did not 
demonstrate a significant difference in their sleep onset attempt (bedtime) and morning waking. 
However, they reported a significantly longer sleep onset delay. The postnatal PPCM group also 
reported higher sleep fragmentation, as well as shorter periods between waking. There was no 
difference in ease to wake up between the groups, but the PPCM women did report significantly 
















































4.2 The serum BNP concentration is elevated in the postpartum women with PPCM 
 
Elevated levels of serum BNP or NT-pro BNP are established markers of heart failure12. BNP has an 
important role in the regulation of cardiovascular and renal homeostasis, as well as in the regulation 
of fatty acid metabolism and body weight12. The serum concentrations of  BNP rise in pathological 
states, such as in ventricular dilation or reduced clearance of peptides (renal failure)12. Studies have 
shown a direct correlation between cardiac damage and BNP concentration12. A study by Sliwa et al. 
demonstrated an increase in the NT-pro BNP at baseline in postpartum women with PPCM17. 
In the present study, the BNP levels in the serum of pregnant and postpartum HC, CD and PPCM 
women were quantified. The ESC guideline cut-off for healthy non-cardiac failure BNP levels are 
100pg/mL108. The results of our study showed an increase in the BNP levels in the postpartum 
women with PPCM. The mean BNP concentration in the PPCM group was above the guideline cut 
off for normal BNP concentrations. There was a large variation in the PPCM group, most likely due 
to a large variation in the severity of HF. There was also a large variation in BNP levels of CD 
women, due to the large spectrum of their conditions. The levels of BNP in the CD women, may be 
lower due to their careful monitoring and treatment during pregnancy. There was no difference in the 
BNP levels of the pregnant PPCM women compared to the CD or HC women. This may be due to 
the fact that the women were previously diagnosed with PPCM and monitored and treated carefully 
during the subsequent pregnancy.  
These results reinforce the previous studies and indicate that postpartum women diagnosed with 
PPCM have an increase in BNP levels as a result of heart failure due to LV dilation.  Some women 
with PPCM do recover normal LV function and their hearts return to normal26. The discrepancy in 
severity also possibly explains why some women with PPCM recover LV function and their hearts 


















4.3 The serum MDA, a product of lipid peroxidation is elevated in the postpartum PPCM 
group.    
 
Oxidative stress has been shown to play a central role in the pathogenesis of cancer, atherosclerosis, 
aging and other chronic diseases40. Sustained increases in oxygen radical production in the 
mitochondria may lead to a destructive cycle of mitochondrial DNA  damage, as well as functional 
decline, further ROS generation and cellular injury42. A study conducted by Hilfiker-Kleiner et al. 
found that, in a mouse model of PPCM with a cardiomyocyte specific deletion in STAT3, they had 
increased oxidative stress and cathpepsin D18. This oxidative stress mediates the cathpepsin D 
cleavage of the nursing hormone, prolactin, into a 16kDa pro apoptotic form and develop the 
hallmarks of PPCM18. Hilfiker-Kleiner et al. performed further studies in humans and demonstrated 
a reduction in the STAT-3 protein in the heart tissue of women with PPCM, in comparison to healthy 
controls19. In the present study, the oxidative status in the plasma of the postpartum and pregnant 
women with PPCM was compared to that of the CD and HC controls. The ROS and RNS 
demonstrated very short half lives. It is therefore preferable to measure  a decrease in total 
antioxidant capacity or  by the estimation, the products of oxidation of lipids or DNA such as MDA 
and isoprostanes33 109. The present study utilised the TBARS assay to measure the lipid peroxidation 
product, MDA, as well as to assess the antioxidant capacity compared to the vitamin E analogue, 
trolox, using the ORAC assay. 
 
The MDA concentration in the pregnant and postnatal women combined was higher in the PPCM 
women than in the HC, but not the CD women. The average value for healthy non-pregnant subjects 
reported by Jentzsch et al. was 0.47± 0.12 µmol/1110. Our HC values were close to this range but the 
PPCM group values were considerably higher. The pregnant PPCM group was not significantly 
different compared to the pregnant HC and CD group. The CD group did appear elevated compared 
to the HC and PPCM during pregnancy, but not significantly. This may be due to other factors such 
as elevated lipids or other causes of oxidative stress in the various CD women. In contrast, MDA 
concentration was significantly higher in the postpartum PPCM women compared to both the CD 
and HC. This suggests that there is an increase in oxidative stress in the form of lipid peroxidation 
specific to the postpartum PPCM women. This reflects the observation by Hilfiker-Kleiner.et al., 
when the women with PPCM studied demonstrated an increase in oxLDL compared to controls19. 
 
Oxidative stress increases in the final trimester of pregnancy, however, this returns to normal in 












involves the ROS and RNS metabolic pathway activation during early pregnancy to facilitate 
pregnancy related changes28. The increase in oxidative stress in healthy women peaks during the 
second trimester38. This early physiological increase in oxidative stress may be the reason why 
previous studies such as the VIP trial, using antioxidants in high concentrations to prevent pre-
eclampsia, failed43. These high concentrations may even worsen increased oxidative stress later in 
pregnancy as the high doses may lead to the loss of the endogenous antioxidant protection. Lower 
doses of appropriate antioxidants given later in pregnancy may prevent conditions related to 
oxidative stress such as PPCM and pre-eclampsia. Further studies are required to test this hypothesis. 
An increase in oxidative stress during pregnancy can be characterised by enhanced lipid per 
oxidation and the circulation of lipid hydroperoxides and MDA (measured using the TBARS 
assay)28.  
 
In our study, the HC third trimester pregnant women did have a marginally higher MDA 
concentration than the HC postpartum women. This is likely due to the residual of the increase in the 
first and second trimesters. When the pregnancy is advanced, disruption in this oxidative balance can 
lead to an incorrect activation of the inflammatory cascade which produces harmful effects, 
including premature labour and complications such as pre eclampsia28. There was no statistically 
significant difference between the pregnant PPCM compared to the CD and HC women however, the 
means were marginally higher which may cause the PPCM and CD women to be more at risk for 
pre-eclampsia, frequently associated with PPCM21. The pregnant PPCM group may not be 
significantly higher due to the variations in pregnancy and the differences within the PPCM group of 
women at higher risk for reoccurrence.  
 
In light of the increased oxidative stress in the PPCM, an ORAC assay was performed on the 
remaining plasma samples. There was no observable difference in the antioxidant capacity of the 
samples, as determined by the ORAC assay. These data, however, do not exclude a decrease in total 
antioxidant capacity as the ORAC only measures the vitamin E equivalent antioxidant capacity. The 
antioxidant capacity in the samples degrade over time and with freeze-thaw cycles.  Therefore, only 















4.4 The mean EDPS score is elevated in postpartum PPCM women and pregnant CD women 
compared to HC. 
 
To screen for possible depression, the EPDS was administered to the pregnant and postpartum HC, 
CD and PPCM women. The EPDS is a validated 10 item questionnaire used for screening for a 
probable diagnosis of depression both pre- and postpartum85 82. Depression is known to be a risk 
factor for the development of cardiovascular disease, as well as a predictor of poor prognosis 
following a cardiac event96. The mechanism by which depression is thought to contribute is through 
an increase in oxidative stress, as well as inflammation99. Depression has previously been shown to 
increase inflammatory markers such as CRP, TNF-α and IL6, that have all been associated with an 
increased risk for cardiovascular disease99. The psychosocial risk factors for maternal and 
postpartum depression include past history of mental illness, mental disturbance during pregnancy, 
family history of depression, low socioeconomic status and poor interpersonal relationships87. Risk 
factors for depression during and following maternity include low education,  psychosocial stressors 
and  if previous history of depression were trimester dependant88. In developed countries, studies 
have shown that the prevalence of postpartum depression is around 10-15% - in developing regions 
this figure is 2-3 fold higher82. Two separate studies performed in South Africa found a prevalence of 
32% and 39% of possible depression in healthy postpartum women, using the EDPS scale84 85.  
The recommended cut-off point for EDPS score is 10 for possible depression and 20 for possible 
severe depression. In our study, similar to the literature, a third of the pregnant and postpartum HC 
women, and two-thirds of both CD and PPCM women, had a EDPS score above 10. Although the 
EDPS scores of the postpartum PPCM women are elevated compared to the HC women, they are not 
significantly elevated compared to the CD group. The average score of the PPCM group is higher, 
which possibly indicates more frequent or severe depression. A previous study has suggested that 
depression and anxiety in early pregnancy are a risk factor for pre eclampsia later in pregnancy103. A 
similar pattern may be found for PPCM, however it is out of the scope of the present study. The 
PPCM women may have been depressed before the onset of PPCM, or they may have developed the 
depression subsequent to the condition. The CD women displayed a higher depression score during 
pregnancy.  As a large number are due to congenital heart disease, their heart condition may affect 
their lives in such a way that leads to depression. A possible explanation for the increase in the 
postpartum PPCM women is that previous depression contributed to the development of PPCM, and 
the development of PPCM worsened their depression. The EDPS scale is a self-report scale and 












also only a screening tool - an elevated score warrants further investigation by a qualified mental 
health practitioner. During the questionnaire interview, it was noted that many of the CD and PPCM 
women reported feeling anxiety about dying from their condition.  The high scores were often due to  
fear and anxiety, as well as sleep-based questions, rather than the mood-specific questions. This may 
indicate that the scale may be measuring depression itself, but also anxiety disorders. The scale has 
been validated previously in a South African population. During the interviews I found that some 
women had difficulty understanding.  In particular, the first question, " Are you still able to laugh 
and see the funny side of things". The questions often had to be explained to the participants. I would 
recommend the scale be reworded and validated for the South African population, particularly if it is 
to be in studies where the questionnaire is self-administered.  
Peripartum depression is disabling for women and is most common during the childbearing years81. 
Appropriate screening tools should be implemented, especially in developing countries where the 
prevalence is higher. The mental and physiological changes of the depressive women may potentially 
negatively affect the course of the disease96. The depressed PPCM and CD women may not adhere to 
treatment and their condition may worsen or, in the case of PPCM, the heart may not normalise. 
Previous studies have shown that depressed postpartum women also had lower levels of prolactin 
and that breastfeeding women have lower EDPS scores93. Bromocriptine, an inhibitor of prolactin 
release from the pituitary gland, is now commonly used to treat PPCM11. The PPCM women are 






















4.5 The postnatal PPCM women report lower sleep efficacy, fragmented sleep and a greater 
sleep onset delay 
 
The sleeping patterns in pregnant and postpartum women are disturbed, compared to non pregnant 
women. Pregnant women also wake up more frequently as the foetus grows and these women often 
suffer nocturia and difficulty in sleeping comfortably54. Oestrogen and progesterone are known 
modulators of the amplitude and phase of the circadian rhythm54. It is possible that changes in these 
hormones during pregnancy may alter the rhythm in these women, predisposing them to mood 
alterations, as well as sleep disruption54. Melatonin, as well as the circadian sleep rhythm, have been 
demonstrated to be disturbed in the postpartum period47. Postpartum women often wake up more 
frequently to care for their infant47. Humans can be classified as either "evening people" or "morning 
people",  morning people, tend to be more fatigued at night and rise earlier51. "Evening people" tend 
to be more active at night and rise later in the morning, with more fatigue51.  Data suggests that these 
differences are due to individual differences in the timing and onset of melatonin release51. Circadian 
rhythm disturbance is also a major feature of mood disturbances54. 
 
Even though the postpartum PPCM women tried to sleep at the same time as the HC and CD women, 
it took them longer to fall asleep. This may be due to the symptoms of PPCM or other factors, such 
as a sleep disorder or depression, Orthopnoea is a common symptom and could contribute to 
difficulty falling asleep.  All the pregnant and postpartum women reported an increase in sleep 
disruption and sleep fragmentation, compared to before pregnancy. The postpartum PPCM women 
reported a higher frequency than the postpartum CM and HC women in nocturnal waking, longer 
time between sleep and longer waking time compared to the CD and HC women. This may again be 
due to the symptoms of PPCM, such as palpitations, or may have another underlying cause. The 
PPCM women also reported less energy following waking, compared to the HC group. The 
symptoms of PPCM include fatigue and may contribute to the reports of fatigue, compared to the HC 
group. 
 
Circadian rhythm disturbance is also a major feature of mood disturbances54. Sleep disruption is a 
common symptom of both postpartum depression and major depression. Sleep disruption may also 
lead to a lower mood. Whether the PPCM symptoms caused the sleep disruption, which may lead to 












4.6  The serum cortisol concentrations are elevated in pregnant and postpartum women with 
PPCM  
 
The steroid hormone cortisol, is released in response to stress and is commonly elevated in 
psychiatric conditions such as anxiety and depression89. There has been previous reports noting an 
increase in blood cortisol during pregnancy, with a 2- to 3-fold increase in the final trimester91. In 
healthy women the cortisol levels return to baseline shortly following birth.  
There was a significant increase in serum cortisol in the postpartum women with PPCM. In the 
present study cortisol concentrations in pregnant and postpartum HC, CD and PPCM women was 
quantified. The mean serum cortisol in healthy pregnant women was almost 2-fold higher than in 
healthy postpartum women. This is in keeping with previous reports of the increase in cortisol during 
pregnancy. There was no significant difference in serum cortisol during pregnancy between the 
groups.  
There was a positive correlation between cortisol levels and EDPS scores in the postpartum women. 
There was no correlation between the EDPS score and cortisol level during pregnancy and this may 
be due to the natural disruption of cortisol and other pregnancy related factors. Alternately, other 
factors during pregnancy, such as anxiety, which is not measured by EDPS, may affect the 
correlation. There was a mildly positive correlation between cortisol and EDPS scores during the 
postpartum period.  
This suggests an increase in stress or a psychiatric condition such as depression. This correlated to an 
increase in the EDPS score, suggesting that postpartum women with PPCM are more depressed than 
controls. This, however, cannot determine whether the increase in stress/anxiety/depression 
contributes towards the development of PPCM or whether the increase in stress is due to the stress of 
being diagnosed with a potentially life-threatening condition. There were many women in the study 
who reported a fear of dying.  The was also an increase, however not significantly, in the CD group 
compared to the HC group. This may be lower than the PPCM group due to the variation in the 
severity of their conditions. There was no significant difference in the postpartum cortisol levels of 
the CD women compared to the PPCM women. This may suggest that the increase in stress is due to 
the condition and not a contributor. The only method to determine whether stress and an increase in 














4.7 Salivary melatonin is elevated in the postpartum PPCM women 
 
 Melatonin is renowned as a "sleep hormone" and acts as a time-giver, essential to both the timing 
and onset of circadian rhythm and reproduction46. Human average melatonin levels are lowest during 
daytime hours and peak around 2-4am and decrease towards the morning hours50. Melatonin is also a 
powerful natural antioxidant, able to easily reach cellular and sub cellular compartments, due to its 
small size and amphiphilic nature47. Melatonin has previously been shown to activate the 
cardioprotective SAFE pathway that involves the activation of TNF and STAT360. Preliminary 
studies suggest melatonin levels are lower in subjects with coronary artery diesease 45. Evidence in 
the literature indicate that melatonin is a potential therapy, either alone or in combination, in 
conditions with oxidative stress32. Melatonin has multiple pleiotrophic effects on the heart, including 
anti-inflammatory, antioxidant and antihypertensive effects58. In women with severe pre-eclampsia, 
the serum melatonin levels have been shown to be significantly lower 46. Pre-eclampsia is another 
cardiovascular disease associated with pregnancy. Melatonin was hypothesised to show a similar 
decrease in PPCM. 
The nocturnal (2am) and daytime (baseline) salivary mel tonin concentration was determined in the 
pregnant and postnatal HC, CD and PPCM women by ELISA. Unlike the women with severe pre-
eclampsia, we were surprised to find that the postpartum PPCM women demonstrated significantly 
higher nocturnal melatonin, compared to the CD and HC women. The daytime melatonin levels were 
also slightly elevated, but not significantly. Melatonin concentrations during pregnancy have been 
shown to be suppressed in the first trimester with the increase in oxidative stress and, thereafter, rise 
and return to baseline postpartum46. Depressed pregnant and postpartum women have been shown to 
have different patterns in melatonin concentrations. Depressed pregnant women have previously 
been shown to have lower melatonin levels and depressed postpartum women higher melatonin 
levels than controls105 54. The postnatal PPCM women demonstrated higher cortisol and EDPS scores 
postpartum, which may explain the increase in nocturnal melatonin. The PPCM women also reported 
more sleep fragmentation and sleep efficiency, logically this would indicate lower melatonin 
concentrations. A previous study found the inverse, that lower sleep quality was correlated with 
higher melatonin concentrations104. This has been suggested to be due to the natural defence 
response to increase in oxidative stress caused by change in diet or lifestyle in response to mental 
stress104. Chronic poor sleep quality is likely to increase the melatonin concentration in as a defence 













Melatonin has also been shown to suppress prolactin secretion in animal models (rats and ewes)55 54. 
This suggests that melatonin and prolactin may also have a similar relationship in humans. If 
melatonin supplementation has the effect of inhibiting prolactin, possibly the inhibition of prolactin 
may raise the levels of melatonin. Bromocriptine, an inhibitor of prolactin secretion, has been 
suggested as a potential treatment for PPCM and 7 of the 9 postnatal PPCM women in this study 
received treatment with the drug. The increased levels of melatonin may act as a natural endogenous 
mechanism to limit the progression of the disease. It would be relevant to study whether 
bromocriptine suppresses prolactin secretion, in part, by raising melatonin.  
 
There are individual differences in the timing and onset of the release of melatonin51. The nocturnal 
melatonin was only sampled at 2am. A full 24-hour sampling every hour would be required to 
compare the full melatonin rhythm. Hence, the observed increase may be due to a shift in the release 
in melatonin levels in the PPCM group, with an earlier release leading to a higher concentration. 
Melatonin should be measured under controlled light conditions as even dim light can suppress 
melatonin release.  Variations may therefore be observed in women who did not fully adhere to the 
written instructions 50.   
 
Although the results suggest an increase in melatonin in the PPCM group, melatonin should not be 
excluded as a potential prevention or treatment in cardiovascular disease such as PPCM. Previous 
studies have failed to show a benefit using supplementation with classical antioxidant vitamins A,E 
and C32. Melatonin is a powerful  scavenger of both RNS and ROS, including those formed from 
peroxynitrite, and blocks transcriptional factors, which induce pro inflammatory cytokines, as well as 
presenting additional benefits independent of its antioxidant capacity32. The use of exogenous 
melatonin supplementation has previously been reported to induce drowsiness and sleep and has 
been suggested to be beneficial in alleviating sleep disturbances and nocturnal akawkenings52. There 
have been other beneficial effects of melatonin supplementation during pregnancy, such as the 


















4.8 Limitations to study 
 
The samples size of the study was relatively small and collected from a single centre (CDMC). The 
study used two questionnaires to measure depression scores and sleep disruption. Questionnaires are 
notoriously subjective and participants tend towards more socially desirable answers, as well as 
understating or exaggeration of answers. The study was also limited by the willingness of 
participants to collect their own saliva samples and return them the following day. While the utmost 
care was taken to correctly instruct the patients to avoid bright light and collect the samples at the 
correct time, this cannot be guaranteed. Ideally the saliva samples should have been sampled hourly, 
to obtain a detailed pattern of the release of melatonin. Due to most of the PPCM women only being 
diagnosed in the postpartum phase, it is impossible to determine whether the sleep disruption, 
depression, melatonin and cortisol levels are a result of or a contributing factor in the development of 
PPCM. Also most of the postnatal PPCM women received bromocriptine, which could not be 
controlled. This may affect the oxidative stress assays, as well as the depression score results. 
Furthermore, bromocriptine may likely have raised the melatonin levels in the postnatal PPCM 
women. The number of pregnancies of the patients was also not reported and multiple pregnancies 
may affect oxidative stress and depression levels. While the blood samples were handled carefully, 
there was loss of samples due to haemolysis of the blood being excluded from the oxidative stress 

























The postpartum women diagnosed with PPCM showed higher concentrations of BNP and an 
increase in oxidative stress in the form of lipid peroxidation, corresponding with previous findings. 
The PPCM group had higher EDPS scores with higher serum cortisol, as well as signs of sleep 
disruption. In the future, a possible study could be widespread screening of pregnant women, at 
multiple centres, during pregnancy to determine whether they are more at risk for the development of 
PPCM or other conditions. Conditions such as peripartum depression are more common in 
developing countries, such as South Africa, and there is a need for  more efficient screening 
methods, as well as treatment, as these conditions have a detrimental effect on the health of the 
population. 
 Unlike the study on severe pre-eclampsia, also thought to be the result of an increase in oxidative 
stress where the melatonin levels were lowered, the postpartum PPCM group demonstrated higher 
melatonin levels. Further studies with a larger sample size are needed to determine whether this 
increase is due to Bromocriptine treatment, as a possible defence mechanism in response to the 
increase in oxidative stress or a shift in melatonin in secretion. 
In developing countries, there is a higher prevalence of PPCM and a high mortality rate, with 
approximately 1 in 5 women dying, even on treatment. It is therefore important that cost-effective, 
safe and effective alternative treatments or prevention strategies be found. The potential benefits of 
melatonin use are outlined in Figure 43. If melatonin proves to be an important mediator of 
bromocriptine-induced suppression of prolactin, the use of low dose melatonin supplementation may 
prove to be a more desirable alternative. Bromocriptine cannot be used during pregnancy, while the 
use of low doses of melatonin has additional benefits during pregnancy. Bromocriptine also has 
undesirable side-effects, such as the full suppression of breastfeeding, as well as the reported 
thrombotic risks. Supplementation with exogenous melatonin may allow for the safe reduction in 
prolactin and a reduction in the oxidative stress, which has been shown to contribute to the 
development of PPCM. Melatonin has the additional benefits, to regulate sleeping pattern and 
antidepressant effects, common symptoms observed in the women with PPCM. Melatonin has 
previously been shown to be antihypertensive, which may be beneficial due to the high co morbidity 
with pre-eclampsia. There should be caution with the timing of melatonin as supplementation, as it 
may not be beneficial in the first trimester where oxidative stress has necessary physiological 












treatment and even, possibly,  prevent PPCM. If these studies prove beneficial, melatonin may be a 
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Phosphate buffer(0.075M pH=7.4):  
  0.75M K2HPO4.3H20 (MW= 228.23: 85.6g →500mL d H20) 
 0.75M Na2H2PO4.H20 (MW= 137.99: 51.8g →500mL d H20) 
 
90mL K2HPO4 +24mL Na2H2PO4 
Make up to 900mL then pH , make up to 1L 
 
Trolox:(6-OH-2,5,7,8-tetromethylchorman-2-carboxylic acid) 
0.005g Trolox in 200µl ethanol = 100mM 
1. 100µl + 9.9 µl buffer  =1000µM 
2. 1mL   + 9mL buffer  =100µM (5nmol) 
3. 300µl +300 µl buffer  =50 µM (2.5nmol) 
4. 300µl +300 µl buffer  =25 µM (1.25nmol) 
5. 300µl +300 µl buffer  =12.5 µM (0.625nmol) 
6. 300µl +300 µl buffer  =6.25 µM (0.313nmol) 
7. 300µl +300 µl buffer  =3.13 µM (0.156nmol) 
8. 300µl +300 µl buffer  =1.37 µM (0.078nmol) 
Fluorescien (3,6-dihydroxyspiro(isoberyofuran-1(3H),9(9H)-xanthen) (disodium) 
 Stock 1: 0.0225g in 50mL buffer (0.0011959 mol/L) 
 Stock 2: 50µl stock 1 in 10mL buffer 1 in 10m/L buffer (5.98µmol/L) 
 Working solution: 320µl stock 2 in 20mL buffer (95.7nmol/L) 
 
 
AAPH: (2,2 -azobis(2-andinopropane)dihydrocholride) 
NB: Prepare immediately before use in phos. buffer pre washed to 37°C 
 0.087g + 980µl warm buffer 
 (0.348g + 3920µl warm buffer) =32.1 µmol per well  
 0.696 + 7840 warm buffer 
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